EVAN MAYO-WILSON, DPHIL, MPA

CONTACT INFORMATION

Department of Epidemiology
UNC Gillings School of Global Public Health
2101C McGavran-Greenberg Hall
Chapel Hill, NC 27599
Email: evan.mayo-wilson@unc.edu
ORCID: 0000-0001-6126-2459

EDUCATION

2011	DPhil (PhD)	Department of Social Policy and Intervention, University of Oxford, Oxford, UK
2006	MPA	Fels Institute of Government, University of Pennsylvania, Philadelphia, PA
2004	MSc	Department of Social Policy and Intervention, University of Oxford, Oxford, UK
2003	BA	Columbia College (Honors Psychology), Columbia University, New York, NY

PROFESSIONAL EXPERIENCE

2022—present	Associate Professor Department of Epidemiology, UNC Gillings School of Global Public Health
2019—2022	Associate Professor (tenure awarded 2022) Department of Epidemiology & Biostatistics, Indiana University School of Public Health
2018—2019	Associate Scientist Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health
2014—2018	Assistant Scientist Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health
2011—2014	Senior Research Associate Department of Clinical, Educational & Health Psychology, University College London
2007—2011	Departmental Lecturer Department of Social Policy and Intervention, University of Oxford

HONORS AND AWARDS

2025	Clarivate Highly Cited Researchers 2025
2025	Sigma Xi (Full member)
2019	Golden Apple Award (teaching excellence) Johns Hopkins Bloomberg School of Public Health (Baltimore, MD)
2006	Clarendon Scholarship University of Oxford (Oxford, UK)
2004	Fels Scholarship University of Pennsylvania (Philadelphia, PA)

CURRENT MEMBERSHIPS

American Psychological Association (APA)
American Public Health Association (APHA)
American Association for the Advancement of Science (AAAS)
Cochrane

Society for Epidemiologic Research (SER)
Society for Research Synthesis Methodology (SRSM)

PUBLICATIONS

Web of Science: 84,782 times cited, H-index 50
PubMed bibliography: https://www.ncbi.nlm.nih.gov/myncbi/1x7EldN5gnwAH/bibliography/public/

Books and chapters

1. Czajkowski S, Davidson K, Freedland K, **Mayo-Wilson E** (order of authorship is alphabetical) (2025). Chapter 12: Systems of Evidence in Health Psychology. In: Smith T, Anderson NB, Antoni MH, Penedo FJ, Revenson TA, Abraido-Lanza AF (Eds.), *APA Handbook of Health Psychology Volume 1: Foundations and Context of Health Psychology*. American Psychological Association: Washington, DC. ISBN: 978-1-4338-3672-5. DOI: 10.1037/0000394-012.
2. **Mayo-Wilson E**, Grant SP (2019). Transparent Reporting: Registrations, Protocols and Final Reports. In: Cooper H, Hedges LV, Valentine JC (Eds.), *The Handbook of Research Synthesis and Meta-Analysis*, third edition (pp. 471-488). Russell Sage Foundation. ISBN: 978-0871540058. DOI: 10.7758/9781610448864.24.
3. Montgomery P, **Mayo-Wilson E** (2015). Randomized controlled trials and evidence-based practice. In: Corcoran K, Roberts AR (Eds.), *Social Workers' Desk Reference* (pp. 1221-1229). Oxford University Press: Oxford. ISBN: 9780199329649.
4. Montgomery P, **Mayo-Wilson E** (2008). Randomized controlled trials and evidence-based practice. In: Roberts AR (Ed.), *Social Workers' Desk Reference* (pp. 1142-1148). Oxford University Press: Oxford. ISBN: 9780195369373.

Refereed journal articles

1. Ying X, Ninan K, Oberste JP, Vorland CJ, Li T, Brown AW, Menke J, Qureshi R, DeVito NJ, Page MJ, McKenzie JE, Saldanha IJ, Zhang S, Butcher NJ, Offringa M, Cummins J, Kilicoglu H, **Mayo-Wilson E** (2026). An automated approach to improve clinical trial registration and to identify outcome changes on ClinicalTrials.gov. *npj Digital Medicine*. DOI: 10.1038/s41746-026-03045-y. [Protocol on *MetaArXiv*]
2. Ninan K, Oberste JP, Ying X, DeVito NJ, Li T, Blanco D, Grana C, Boutron I, Baldwin-SoRelle C, Kilicoglu H, **Mayo-Wilson E** (2026). Completeness of outcome definitions in clinical trial registrations: A cross-sectional study. *JAMA Network Open*. In press. [Preprint on *MetaArXiv*, Protocol on OSF]
3. Ying X, Li T, McKenzie JE, Page MJ, Ninan K, Oberste JP, Vorland CJ, Brown AW, Qureshi R, DeVito NJ, Saldanha IJ, Offringa M, Butcher NJ, Zhang S, Nguyen PY, Menke JD, Lai VKW, Kilicoglu H, **Mayo-Wilson E** (2026). Guidance for defining outcomes in clinical trials. *PLOS Medicine* 23(10):e1005275. PMID: 42905861. [Preprint on *MetaArXiv*]
4. Oberste JP, Ninan K, Ying X, DeVito NJ, Li T, Blanco D, Grana C, Boutron I, Baldwin-SoRelle C, Kilicoglu H, **Mayo-Wilson E** (2026). Updating key dates and reporting additional information in registrations of ICMJE member journal RCTs: A cross-sectional analysis. Submitted. [Protocol on OSF]
5. Ismail S, Jonsson Funk M, Flythe JE, Edwards J, Stürmer T, Kotzen E, **Mayo-Wilson E** (2026). Comparative effectiveness of belatacept versus tacrolimus for mortality and kidney outcomes among kidney transplant recipients in the United States. Submitted.
6. Ismail S, Jonsson Funk M, Flythe JE, Edwards J, Stürmer T, Kotzen E, **Mayo-Wilson E** (2026). Comparative harms of belatacept versus tacrolimus among kidney transplant recipients. Submitted.
7. Page MJ, **Mayo-Wilson E**, Zeng M, Clark DPQ, Hamilton DG, Nguyen PY, Nussbaumer-Streit B, Ying X, Kilicoglu H, McKenzie JE (2026). Evaluation of automated assessments of systematic review adherence to the PRISMA 2020 statement: Study protocol. *F1000Research* 15:665. DOI: 10.12688/f1000research.180216.1.

8. Das P, Schneider J, **Mayo-Wilson E**, Kilicoglu H, Menke J, Nam D, Ninan K, Oberste JP, Troy AM, Ying X, Holt A, Smalheiser N (2026). Study design indexing in transition: A focused comparison of manual NLM indexing versus transformer-based automated models. *JAMIA Open* 9(5):ooag197. PMID: 42960168. [Preprint on medRxiv] [Data on Illinois Data Bank]
9. He H, Loui M, **Mayo-Wilson E**, Costanza M, Morabia A (2026). Triple-Masked v Double-Masked Review of Articles Submitted to the American Journal of Public Health: A Randomized Controlled Trial. Submitted. [Registered on ClinicalTrials.gov]
10. Pak P, Wang J, Metwally EM, **Mayo-Wilson E**, Engel LS, Ranapurwala S, Hino M, Reeder-Hayes KE, Lund JL (2026). Impact of Hurricanes and Related Extreme Weather Events on Health Outcomes: A Scoping Review. Submitted.
11. Grant SP, Corker KS, Mellor D, Stewart SLK, **Mayo-Wilson E**, Cashin AG, Lagisz M, Moher D, Umpierre D, Barbour V, Buck S, Collins GS, Hazlett HF, Hrynaszkiewicz I, Lee CJ, Parker TH, Rethlefsen ML, Toomey E, Nosek BA (2026). TOP 2025: An update to the Transparency and Openness Promotion Guidelines. *Research Integrity and Peer Review* 11(1):40. PMID: 42557573. [Preprint on *MetaArXiv*]
12. Zeng M, Liu S, Clark DPQ, McDonald S, **Mayo-Wilson E**, Ying X, Menke J, Lan M, Jiang L, Ninan K, Oberste JP, McKenzie JE, Kilicoglu H, Page MJ (2026). Artificial intelligence tools for automating assessments of reporting guideline adherence: A protocol for a systematic review. *F1000Research* 15:626. DOI: 10.12688/f1000research.179775.2.
13. Naylor JA, Jonsson-Funk M, Ranapurwala S, Canham Chervak M, **Mayo-Wilson E**, Bruno MK, Olivarez CV, Marshall SW (2026). Descriptive epidemiology of musculoskeletal injuries presenting to an embedded Holistic Health and Fitness (H2F) team in a United States Army Stryker Brigade, October 2021-September 2022. *Military Medicine* 191(9-10):e2057-e2065. PMID: 41641596.
14. Zhang J, Jia P, Furuya-Kanamori L, Yang Y, **Mayo-Wilson E**, Lin L, Chu H, Gu Z, Loke Y, Fan Z, Golder S, Doi SA, Vohra S, Lin H, Xu C (2026). Reporting of pediatric adverse events in clinical trials that enrolled both children and adults: A cross-sectional survey. Submitted.
15. Wang X, Furuya-Kanamori L, Doi SA, Gu Z, Loke Y, Li S, **Mayo-Wilson E**, Lin L, Golder S, Chu H, Vohra S, Guo X, Xu C (2026). Time-to-expiration for evidence bodies of medication harms (TIME): Survival analysis from a retrospective cohort. *BMC Medicine*. DOI: 10.1186/s12916-026-05296-8.
16. Jiang L, Ying X, Brown AW, Lan M, Song W, Menke JD, Vorland CJ, **Mayo-Wilson E**, Kilicoglu H (2026). SPIRIT-CONSORT-ELM: Element-level annotated dataset and large language model approach for assessing randomized controlled trial reporting. *npj Digital Medicine*. DOI: 10.1038/s41746-026-03318-6. [Preprint on medRxiv]
17. Magwood O, Kuria S, Petkovic J, Todhunter-Brown A, Campbell P, Khabsa J, Lytvyn L, Jull J, **Mayo-Wilson E**, Hilgart J, Ledinger D, Oloyede O, Koscher-Kien C, Dewidar O, Toupin-April K, Welch V, Saginur M, Dawson S, Agarwal A, Horsley T, Akl EA, John D, Tugwell P (2026). Impact of engaging interest-holders in evidence synthesis: A systematic review and categorisation of reported impacts. Submitted.
18. Xu C, Doi SA, Vohra S, Furuya-Kanamori L, Wang Y, Tang L, Tian Y, Fan S, Peng Z, **Mayo-Wilson E**, Lin L, Chu H, Murad MH, Yu T, Li S, Chen Y, Golder S, Loke Y, Clark J, Glasziou P, Du L, Lin H, Gu Z, PROMISE Collaborative Research Network (2026). The Trial Bank Initiative To Promote Trustworthy Living Evidence for Medication Safety (PROMISE) of Children: Design and Pilot Validation. *BMC Medicine* 24(1):181. PMID: 41723462.
19. Fan S, Chen M, Doi SA, Ye Z, Peng Z, Tian Y, Zhang C, Furuya-Kanamori L, Lin L, **Mayo-Wilson E**, Murad MH, Meng X, Xu C (2026). Evaluating data extraction error by a large language model from randomised controlled trials: A large-scale empirical study. *BMJ Evidence-Based Medicine* 31(5):324-331. PMID: 42055792.
20. Todhunter-Brown A, Petkovic J, Chang C, Griebler U, Hannigan A, Hilgart J, Hussain B, Jull J, Koscher-Kien C, Ledinger D, Nussbaumer-Streit B, Oloyede O, Tomlinson E, Dawson S, Dewidar O, Grant S, Lytvyn L, Concannon TW, Dans L, John D, Jordan Z, **Mayo-Wilson E**, McCutcheon C, Nonino F, Pollock D, Toupin April K, Campbell P, Khabsa J, Magwood O, Welch V, Tugwell P (2026). Methods of engaging interest-holders in healthcare evidence syntheses: A scoping review. *Cochrane Evidence Synthesis and Methods* 4(1):e70066. PMID: 41573527. DOI: 10.1002/cesm.70066.

21. **Mayo-Wilson E**, Grant SP, Corker KS, Moher D (2025). Consistent and precise description of research outputs could improve implementation of open science. *Advances in Methods and Practices in Psychological Science* 8(4):25152459251375445. DOI: 10.1177/25152459251375445. [Preprint on *MetaArXiv*]
22. Ying X, Freedland K, Powell L, Stuart E, Ehrhardt S, **Mayo-Wilson E** (2025). Determining sample size for pilot trials: A tutorial. *BMJ* 390:e083405. PMID: 40780848.
23. Ying X, Bougioukas KI, Pieper D, **Mayo-Wilson E** (2025). Weighted corrected covered area (wCCA): A measure of informational overlap among reviews. *Research Synthesis Methods* 16(4):701-708. PMID: 41626914.
24. Jiang L, Vorland CJ, Ying X, Brown AW, Menke JD, Hong G, Lan M, **Mayo-Wilson E**, Kilicoglu H (2025). SPIRIT-CONSORT-TM: A corpus for assessing transparency of clinical trial protocol and results publications. *Scientific Data* 12(1):355. PMID: 40021657. [Preprint on *medRxiv*]
25. Vorland CJ, Brown AW, Kilicoglu H, Ying X, **Mayo-Wilson E** (2024). Publication of results of registered trials with published study protocols, 2011-2022. *JAMA Network Open* 7(1):e2350688. PMID: 38190185. [OSF archive includes data and code]
26. Qureshi R, Naaman K, Quan NG, **Mayo-Wilson E**, Page MJ, Cornelius V, Chou R, Boutron I, Golder S, Bero L, Doshi P, Vassar M, Meursinge Reynders R, Li T (2024). Development and evaluation of a framework for identifying and addressing spin for harms in systematic reviews of interventions. *Annals of Internal Medicine* 177(8):1089-1098. PMID: 39008854. [Online supplements include protocol and research materials]
27. Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Aiyegbusi OL, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, **Mayo-Wilson E**, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M (2024). Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. *Journal of Clinical Epidemiology* 173:111422. PMID: 38849061.
28. Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Aiyegbusi OL, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, **Mayo-Wilson E**, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M (2024). Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. *Quality of Life Research* 33(8):2029-2046. PMID: 38980635.
29. Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Aiyegbusi OL, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, **Mayo-Wilson E**, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M (2024). Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. *Health and Quality of Life Outcomes* 22(1):48. PMID: 38978063.
30. Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Aiyegbusi OL, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, **Mayo-Wilson E**, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M (2024). Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. *Journal of Patient-Reported Outcomes* 8(1):64. PMID: 38977535.
31. Silverstein P, Elman C, Montoya A, McGillivray B, Pennington CR, Harrison CH, Steltenpohl CN, Röer JP, Corker KS, Charron LM, Elsherif M, Malicki M, Hayes-Harb R, Grinschgl S, Neal T, Evans TR, Karhulahti V-M, Krenzer WLD, Belaus A, Moreau D, Burin DI, Chin E, Plomp E, **Mayo-Wilson E**, Lyle J, Adler JM, Bottesini JM, Lawson KA, Schmidt K, Reneau K, Vilhuber L, Waltman L, Gernsbacher MA, Plonski PE, Ghai S, Grant S, Christian TM, Ngiam W, Syed M (2024). A guide for social science journal editors on easing into open science. *Research Integrity and Peer Review* 9(1):2. PMID: 38360805. [Preprint on *OSF Preprints*]
32. **Mayo-Wilson E**, Qureshi R, Hong H, Chen X, Li T (2023). Harms were detected but not reported in six clinical trials of gabapentin. *Journal of Clinical Epidemiology* 164:76-87. PMID: 37871835. [Published protocol; Preprint on MetaArXiv; OSF archive includes data and code]
33. Grant S, **Mayo-Wilson E** (joint first authors), Kianersi S, Naaman K, Henschel B (2023). Open science standards at journals that inform evidence-based policy. *Prevention Science* 24(7):1275-1291. PMID: 37178346. [Published protocol; Preprint on MetaArXiv; OSF archive includes data, code, and materials]

34. Kianersi S, Grant S, Naaman K, Henschel B, Mellor D, Apte S, Deyoe JE, Eze P, Huo C, Lavender BL, Taschanchai N, Zhang X, **Mayo-Wilson E** (2023). Evaluating implementation of the Transparency and Openness Promotion Guidelines: Reliability of instruments to assess journal policies, procedures, and practices. *Advances in Methods and Practices in Psychological Science* 6(1):25152459221149735. DOI: 10.1177/25152459221149735. [Published protocol; Preprint on MetaArXiv; OSF archive includes data and code] OA
35. Naaman K, Grant S, Kianersi S, Supplee L, Henschel B, **Mayo-Wilson E** (2023). Exploring enablers and barriers to implementing the Transparency and Openness Promotion Guidelines: A theory-based survey of journal editors. *Royal Society Open Science* 10(2):221093. PMID: 36756061. [Preprint on MetaArXiv; OSF archive includes data, code, and materials] OA
36. Kilicoglu H, Jiang L, Hoang L, **Mayo-Wilson E**, Vinkers CH, Otte WM (2023). Methodology reporting improved over time in 176,469 randomized controlled trials. *Journal of Clinical Epidemiology* 162:19-28. PMID: 37562729. [GitHub sites include trial data and data from model predictions used in the analysis]
37. Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, **Mayo-Wilson E**, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche P, Moher D, Ioannidis JPA, Vohra S on behalf of the CONSORT Harms Group (2023). CONSORT Harms 2022 statement, explanation, and elaboration: Updated guideline for the reporting of harms in randomised trials. *BMJ* 381:e073725. PMID: 37094878. OA
38. Page MJ, Sterne JAC, Boutron I, Hróbjartsson A, Kirkham JJ, Li T, Lundh A, **Mayo-Wilson E**, McKenzie JE, Stewart LA, Sutton AJ, Bero L, Dunn AG, Dwan K, Elbers RG, Kanukula R, Meerpohl JJ, Turner EH, Higgins JPT (2023). ROB-ME: A tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis. *BMJ* 383:e076754. PMID: 37984978. [Website includes additional materials and guidance] OA
39. Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, **Mayo-Wilson E**, Pham B, Phillips R, Santaguida P, Scherer RW, Gøtzsche P, Moher D, Ioannidis JPA, Vohra S on behalf of the CONSORT Harms Group (2023). CONSORT Harms 2022 statement, explanation, and elaboration: Updated guideline for the reporting of harms in randomized trials. *Journal of Clinical Epidemiology* 158:149-165. PMID: 37100738. OA
40. Imdad A, Rogner J, Sherwani RN, Sidhu J, Regan A, Haykal MR, Tsistinas O, Smith A, Chan XHS, **Mayo-Wilson E**, Bhutta ZA (2023). Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years. *Cochrane Database of Systematic Reviews* 3:CD009384. PMID: 36994923. [Updates previous version; Published protocol]
41. Kahan BC, Hall SS, Beller EM, Birchenall M, Chan AW, Elbourne D, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Juszczak E, Montgomery AA, **Delphi study members (contributor)** (2023). Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. *JAMA* 330(21):2106-2114. PMID: 38051324. OA
42. Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA, **Delphi study members (contributor)** (2023). Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. *JAMA Network Open* 6(12):e2346121. PMID: 38051535. OA
43. **Mayo-Wilson E**, Grant SP, Supplee L (2022). Clearinghouse standards of evidence on the transparency, openness, and reproducibility of intervention evaluations. *Prevention Science* 23(5):774-786. PMID: 34357509. [Preprint on MetaArXiv; OSF archive includes data and code] OA
44. Imdad A, **Mayo-Wilson E**, Haykal MR, Regan A, Sidhu J, Smith A, Bhutta ZA (2022). Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. *Cochrane Database of Systematic Reviews* 3:CD008524. PMID: 35294044. [Updates previous version; Published protocol]
45. Qureshi R, **Mayo-Wilson E**, Rittiphairoj T, McAdams-DeMarco M, Guallar E, Li T (2022). Harms in systematic reviews paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms. *Journal of Clinical Epidemiology* 143:224-241. PMID: 34742790. [Preprint on *OSF* Preprints; OSF archive includes data, code, and materials] OA

46. Qureshi R, **Mayo-Wilson E**, Rittiphairoj T, McAdams-DeMarco M, Guallar E, Li T (2022). Harms in systematic reviews paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin. *Journal of Clinical Epidemiology* 143:212-223. PMID: 34742789. [Preprint on *OSF Preprints*; OSF archive includes data, code, and materials] OA
47. Qureshi R, **Mayo-Wilson E**, Li T (2022). Harms in systematic reviews paper 1: An introduction to research on harms. *Journal of Clinical Epidemiology* 143:186-196. PMID: 34742788. [Preprint on *OSF Preprints*] OA
48. Qureshi R, Chen X, Görg C, **Mayo-Wilson E**, Dickinson S, Golzarri-Arroyo L, Hong H, Phillips R, Cornelius V, McAdams-DeMarco M, Guallar E, Li T (2022). Comparing the value of data visualization methods for communicating harms in clinical trials. *Epidemiologic Reviews* 44(1):55-66. PMID: 36065832. [Online supplement includes code and research materials] OA
49. Grant S, Wendt KE, Leadbeater B, Supplee L, **Mayo-Wilson E**, Gardner F, Bradshaw C (2022). Transparent, open, and reproducible prevention science. *Prevention Science* 23(5):701-722. PMID: 35175501. [Preprint on MetaArXiv] OA
50. Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, **Mayo-Wilson E**, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M (2022). Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. *JAMA* 328(22):2252-2264. PMID: 36511921. [OSF archive includes research materials] OA
51. Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, **Mayo-Wilson E**, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M (2022). Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. *JAMA* 328(23):2345-2356. PMID: 36512367. [OSF archive includes research materials] OA
52. Hansford HJ, Cashin AG, Bagg MK, Wewege MA, Ferraro MC, Kianersi S, **Mayo-Wilson E**, Grant S, Toomey E, Skinner IW, McAuley JH, Lee H, Jones MD (2022). Feasibility of an audit and feedback intervention to facilitate journal policy change towards greater promotion of transparency and openness in sports science research. *Sports Medicine - Open* 8(1):101. PMID: 35932429. [OSF archive includes data and code] OA
53. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2022). A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas. *Revista Panamericana de Salud Pública* 46:e112. PMID: 36601438. OA
54. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2022). A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas. *Epidemiologia e Serviços de Saúde* 31(2). DOI: 10.5123/s1679-49742022000200033. OA
55. **Mayo-Wilson E**, Phillips M, Connor AE, Vander Ley KJ, Naaman K, Helfand MC (2021). Peer review reduces spin in PCORI research reports. *Research Integrity and Peer Review* 6(1):16. PMID: 34847946. [Preprint on MetaArXiv; OSF archive includes data and research materials] OA
56. **Mayo-Wilson E**, Grant S, Supplee L, Kianersi S, Amin A, DeHaven AC, Mellor DT (2021). Evaluating implementation of the Transparency and Openness Promotion (TOP) Guidelines: The TRUST Process for rating journal policies, procedures, and practices. *Research Integrity and Peer Review* 6(1):9. PMID: 34078479. [Preprint on *MetaArXiv*; OSF archive includes research materials] OA
57. **Mayo-Wilson E**, Chen X, Qureshi R, Dickinson SL, Golzarri-Arroyo L, Hong H, Görg C, Li T (2021). Restoring invisible and abandoned trials of gabapentin for neuropathic pain: A clinical and methodological investigation (protocol). *BMJ Open* 11(6):e047785. PMID: 34193496. OA

58. Keyes A, **Mayo-Wilson E**, Nuamah P, Lalji A, Tetteh O, Ford DE (2021). Creating a program to support registering and reporting clinical trials at Johns Hopkins University. *Academic Medicine* 96(4):529-533. PMID: 33060401.
59. Susukida R, Amin-Esmaeili M, **Mayo-Wilson E**, Mojtabai R (2021). Data management in substance use disorder treatment research: Implications from data harmonization of National Institute on Drug Abuse-funded randomized controlled trials. *Clinical Trials* 18(2):215-225. PMID: 33258697.
60. Kanukula R, Page MJ, Dwan K, Turner SL, Loder E, **Mayo-Wilson E**, Li T, Misra A, McDonald S, Forbes AB, McKenzie JE (2021). Development of a checklist to detect errors in meta-analyses in systematic reviews of interventions: Study protocol. *F1000Research* 10:455. PMID: 34249342. OA
61. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 372:n71. PMID: 33782057. [Preprint on MetaArXiv] OA
62. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, *McGuinness* LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE (2021). PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. *BMJ* 372:n160. PMID: 33781993. [Preprint on MetaArXiv] OA
63. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *PLOS Medicine* 18(3):e1003583. PMID: 33780438. OA
64. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Systematic Reviews* 10(1):89. PMID: 33781348. OA
65. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Journal of Clinical Epidemiology* 134:178-189. PMID: 33789819. OA
66. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *International Journal of Surgery* 88:105906. PMID: 33789826. OA
67. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Revista Española de Cardiología* 74(9):790-799. PMID: 34446261. OA
68. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, **Mayo-Wilson E**, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021). Pravila PRISMA 2020.: ažurirane smjernice za izvještavanje u sustavnim pregledima. *Medicina Fluminensis* 57(4):444-465. DOI: 10.21860/medflum2021_264903. OA
69. Keyes A, **Mayo-Wilson E**, Atri N, Lalji A, Nuamah PS, Tetteh O, Ford DE (2020). Time from submission of Johns Hopkins University trial results to posting on ClinicalTrials.gov. *JAMA Internal Medicine* 180(2):317-319. PMID: 31657841. [OSF archive includes data and code] OA

70. Lawson DO, Puljak L, Pieper D, Schandelmaier S, Collins GS, Brignardello-Petersen R, Moher D, Tugwell P, Welch V, Samaan Z, Thombs BD, Nørskov AK, Jakobsen JC, Allison DB, **Mayo-Wilson E**, Young T, Chan A, Briel M, Guyatt G, Thabane L, Mbuagbaw L (2020). Reporting of methodological studies in health research: A protocol for the development of the MethodologIcal STudy reportIng Checklist (MISTIC). *BMJ Open* 10(12):e040478. PMID: 33334836. [OA]
71. **Mayo-Wilson E**, Fusco N, Li T, Hong H, Canner JK, Dickersin K, for the MUDS investigators (2019). Harms are assessed inconsistently and reported inadequately Part 2: Non-systematic adverse events. *Journal of Clinical Epidemiology* 113:11-19. PMID: 31055176. [Published protocol; Dryad archive includes data and code] [OA]
72. **Mayo-Wilson E**, Fusco N, Li T, Hong H, Canner JK, Dickersin K, for the MUDS investigators (2019). Harms are assessed inconsistently and reported inadequately Part 1: Systematic adverse events. *Journal of Clinical Epidemiology* 113:20-27. PMID: 31055175. [Published protocol; Dryad archive includes data and code] [OA]
73. **Mayo-Wilson E**, Fusco N, Hong H, Li T, Canner JK, Dickersin K (2019). Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events. *Trials* 20(1):553. PMID: 31488200. [Published protocol; Dryad archive includes data and code] [OA]
74. Freedland KE, King AC, Ambrosius WT, **Mayo-Wilson E**, Mohr DC, Czajkowski SM, Thabane L, Collins LM, Rebok GW, Treweek S, Cook TD, Edinger JD, Stoney CM, Campo RA, Young-Hyman D, Riley WT, for the National Institutes of Health Office of Behavioral and Social Sciences Research Expert Panel on Comparator Selection in Behavioral and Social Science Clinical Trials (2019). The selection of comparators for randomized controlled trials of health-related behavioral interventions: Recommendations of an NIH expert panel. *Journal of Clinical Epidemiology* 110:74-81. PMID: 30826377.
75. Concannon TW, Grant SP, Welch V, Petkovic J, Selby J, Crowe S, Synnot A, Greer-Smith R, **Mayo-Wilson E**, Tambor E, Tugwell P, for the Multi Stakeholder Engagement (MuSE) Consortium (2019). Practical guidance for involving stakeholders in health research. *Journal of General Internal Medicine* 34(3):458-463. PMID: 30565151. [OA]
76. **Mayo-Wilson E**, Li T, Fusco N, Dickersin K, for the MUDS investigators (2018). Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study). *Research Synthesis Methods* 9(1):2-12. PMID: 29057573. [OA]
77. **Mayo-Wilson E**, Heyward J, Keyes A, Reynolds J, White S, Atri N, Alexander C, Omar A, Ford DE on behalf of the National Clinical Trials Registration and Results Reporting Taskforce Survey Subcommittee (2018). Clinical trial registration and reporting: A survey of academic organizations in the United States. *BMC Medicine* 16(1):60. PMID: 29716585. [OA]
78. **Mayo-Wilson E**, Golozar A, Cowley T, Fusco N, Gresham G, Haythornthwaite JA, Tolbert E, Payne JL, Rosman L, Hutfless S, Canner JK, Dickersin K (2018). Methods to identify and prioritize patient-centered outcomes for use in comparative effectiveness research. *Pilot and Feasibility Studies* 4:95. PMID: 30026961. [Published protocol; Dryad archive includes data and code] [OA]
79. Dickersin K, **Mayo-Wilson E** (2018). Standards for design and measurement would make clinical research reproducible and usable. *Proceedings of the National Academy of Sciences* 115(11):2590-2594. PMID: 29531086. [OA]
80. Grant SP, **Mayo-Wilson E**, Montgomery P, Macdonald G, Michie S, Hopewell S, Moher D on behalf of the CONSORT–SPI Group (2018). CONSORT-SPI 2018 explanation and elaboration: Guidance for reporting social and psychological intervention trials. *Trials* 19(1):406. PMID: 30060763. [Published protocol; UK Data Service ReShare archive includes data] [OA]
81. Li T, **Mayo-Wilson E**, Fusco N, Hong H, Dickersin K (2018). Caveat emptor: The combined effects of multiplicity and selective reporting. *Trials* 19(1):497. PMID: 30223876. [OA]
82. Montgomery P, Grant SP, **Mayo-Wilson E**, Macdonald G, Michie S, Hopewell S, Moher D on behalf of the CONSORT-SPI Group (2018). Reporting randomised trials of social and psychological interventions: The CONSORT-SPI 2018 Extension. *Trials* 19(1):407. PMID: 30060754. [Published protocol; UK Data Service ReShare archive includes data] [OA]

83. Appelbaum M, Cooper H, Kline R, **Mayo-Wilson E** (order of authorship is alphabetical), Nezu AM, Rao S (2018). Journal article reporting standards for quantitative research in psychology: The APA Publications and Communications Board task force report. *American Psychologist* 73(1):3-25. PMID: 29345484. [OA]
84. **Mayo-Wilson E**, Li T, Fusco N, Bertizzolo L, Canner JK, Cowley T, Doshi P, Ehmsen J, Gresham G, Guo N, Haythornthwaite JA, Heyward J, Hong H, Pham D, Payne JL, Rosman L, Stuart EA, Suarez-Cuervo C, Tolbert E, Twose C, Vedula S, Dickersin K (2017). Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. *Journal of Clinical Epidemiology* 91:95-110. PMID: 28842290. [Published protocol; Dryad archive includes data and code] [OA]
85. **Mayo-Wilson E**, Fusco N, Li T, Hong H, Canner JK, Dickersin K, for the MUDS Investigators (2017). Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis. *Journal of Clinical Epidemiology* 86:39-50. PMID: 28529187. [Published protocol; Dryad archive includes data and code] [OA]
86. **Mayo-Wilson E**, Ng SM, Chuck RS, Li T (2017). The quality of systematic reviews about interventions for refractive error can be improved: A review of systematic reviews. *BMC Ophthalmology* 17(1):164. PMID: 28870179. [Data and research materials included in additional files attached to the article] [OA]
87. Imdad A, **Mayo-Wilson E**, Herzer K, Bhutta ZA (2017). Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. *Cochrane Database of Systematic Reviews* 3:CD008524. PMID: 28282701. [Published protocol]
88. Oud M, **Mayo-Wilson E**, Braidwood R, Schulte P, Jones SH, Morriss R, Kupka R, Cuijpers P, Kendall T (2016). Psychological interventions for adults with bipolar disorder: Systematic review and meta-analysis. *British Journal of Psychiatry* 208(3):213-222. PMID: 26932483. [OA]
89. Cybulski L, **Mayo-Wilson E**, Grant S (2016). Improving transparency and reproducibility through registration: The status of intervention trials published in clinical psychology journals. *Journal of Consulting and Clinical Psychology* 84(9):753-767. PMID: 27281372. [OSF archive includes data and research materials]
90. **Mayo-Wilson E**, Doshi P, Dickersin K (2015). Are manufacturers sharing data as promised? *BMJ* 351:h4169. PMID: 26407814.
91. **Mayo-Wilson E**, Hutfless S, Li T, Gresham G, Fusco N, Ehmsen J, Heyward J, Vedula S, Lock D, Haythornthwaite J, Payne JL, Cowley T, Tolbert E, Rosman L, Twose C, Stuart EA, Hong H, Doshi P, Suarez-Cuervo C, Singh S, Dickersin K (2015). Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: A protocol. *Systematic Reviews* 4:143. PMID: 26525044. [OA]
92. Clarke K, **Mayo-Wilson E**, Kenny J, Pilling S (2015). Can non-pharmacological interventions prevent relapse in adults who have recovered from depression? A systematic review and meta-analysis of randomised controlled trials. *Clinical Psychology Review* 39:58-70. PMID: 25939032.
93. Mavranezouli I, **Mayo-Wilson E**, Dias S, Kew K, Clark DM, Ades AE, Pilling S (2015). The cost effectiveness of psychological and pharmacological interventions for social anxiety disorder: A model-based economic analysis. *PLOS ONE* 10(10):e0140704. PMID: 26506554. [OA]
94. Stafford MR, **Mayo-Wilson E**, Loucas CE, James A, Hollis C, Birchwood M, Kendall T (2015). Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: A systematic review and meta-analysis. *PLOS ONE* 10(2):e0117166. PMID: 25671707. [OA]
95. Yesufu-Udechuku A, Harrison B, **Mayo-Wilson E**, Young N, Woodhams P, Shiers D, Kuipers E, Kendall T (2015). Interventions to improve the experience of caring for people with severe mental illness: Systematic review and meta-analysis. *British Journal of Psychiatry* 206(4):268-274. PMID: 25833867. [OA]
96. Sherman LW, Strang H, **Mayo-Wilson E**, Woods DJ, Ariel B (2015). Are restorative justice conferences effective in reducing repeat offending? Findings from a Campbell systematic review. *Journal of Quantitative Criminology* 31(1):1-24. DOI: 10.1007/s10940-014-9222-9. [Published protocol] [OA]

97. Ades AE, Lu G, Dias S, **Mayo-Wilson E**, Kounali D (2015). Simultaneous synthesis of treatment effects and mapping to a common scale: An alternative to standardisation. *Research Synthesis Methods* 6(1):96-107. PMID: 26035473. [OA]
98. Cargo M, Stankov I, Thomas J, Saini M, Rogers P, **Mayo-Wilson E**, Hannes K (2015). Development, inter-rater reliability and feasibility of a checklist to assess implementation (Ch-IMP) in systematic reviews: The case of provider-based prevention and treatment programs targeting children and youth. *BMC Medical Research Methodology* 15:73. PMID: 26346461. [OA]
99. Nosek BA, Alter G, Banks G, Borsboom D, Bowman S, Breckler S, Buck S, Chambers C, Chin G, Christensen G, Contestabile M, Dafoe A, Eich E, Freese J, Glennerster R, Goroff D, Green DP, Hesse B, Humphreys M, Ishiyama J, Karlan D, Kraut A, Lupia A, Mabry PL, Madon T, Malhotra N, **Mayo-Wilson E** (order of authorship is alphabetical after the first author), McNutt M, Miguel E, Paluck EL, Simonsohn U, Soderberg C, Spellman B, Turitto J, VandenBos G, Vazire S, Wagenmakers EJ, Wilson RK, Yarkoni T (2015). Promoting an open research culture. *Science* 348(6242):1422-1425. PMID: 26113702. [OA]
100. **Mayo-Wilson E**, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, Pilling S (2014). Psychological and pharmacological interventions for social anxiety disorder in adults: A systematic review and network meta-analysis. *The Lancet Psychiatry* 1(5):368-376. PMID: 26361000. [Registered protocol; Data and code in Appendix A and Appendix B] [OA]
101. **Mayo-Wilson E**, Junior JA, Imdad A, Dean S, Chan XH, Chan ES, Jaswal A, Bhutta ZA (2014). Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years of age. *Cochrane Database of Systematic Reviews* 5:CD009384. PMID: 24826920. [Published protocol]
102. **Mayo-Wilson E**, Grant SP, Burton J, Parsons A, Underhill K, Montgomery P (2014). Preventive home visits for mortality, morbidity, and institutionalization in older adults: A systematic review and meta-analysis. *PLOS ONE* 9(3):e89257. PMID: 24622676. [Published protocol] [OA]
103. **Mayo-Wilson E**, Imdad A, Junior J, Dean S, Bhutta ZA (2014). Preventive zinc supplementation for children, and the effect of additional iron: A systematic review and meta-analysis. *BMJ Open* 4(6):e004647. PMID: 24948745. [Published protocol] [OA]
104. Brown TW, van Urk FC, Waller R, **Mayo-Wilson E** (2014). Centre-based day care for children younger than five years of age in low- and middle-income countries. *Cochrane Database of Systematic Reviews* 9:CD010543. PMID: 25254354. [Published protocol]
105. van Urk FC, Brown TW, Waller R, **Mayo-Wilson E** (2014). Centre-based day care for children younger than five years of age in high-income countries. *Cochrane Database of Systematic Reviews* 9:CD010544. PMID: 25247266. [Published protocol]
106. Grant SP, Parsons A, Burton J, Montgomery P, Underhill K, **Mayo-Wilson E** (2014). Home visits for prevention of impairment and death in older adults: A systematic review. *Campbell Systematic Reviews* 10(1). DOI: 10.4073/csr.2014.3. [Protocol] [OA]
107. Harrison B, **Mayo-Wilson E** (2014). Trial registration: Understanding and preventing bias in social work research. *Research on Social Work Practice* 24(3):372-376. DOI: 10.1177/1049731513512374.
108. Lloyd-Evans B, **Mayo-Wilson E**, Harrison B, Istead H, Brown E, Pilling S, Johnson S, Kendall T (2014). A systematic review and meta-analysis of randomised controlled trials of peer support for people with severe mental illness. *BMC Psychiatry* 14:39. PMID: 24528545. [OA]
109. Kendall T, Morriss R, **Mayo-Wilson E**, Marcus E (2014). Assessment and management of bipolar disorder: Summary of updated NICE guidance. *BMJ* 349:g5673. PMID: 25258392.
110. **Mayo-Wilson E**, Montgomery P (2013). Media-delivered cognitive behavioural therapy and behavioural therapy (self-help) for anxiety disorders in adults. *Cochrane Database of Systematic Reviews* 9:CD005330. PMID: 24018460. [Published protocol]
111. Montgomery P, Grant SP, Hopewell S, Macdonald G, Moher D, Michie S, **Mayo-Wilson E** (2013). Protocol for CONSORT-SPI: An Extension for social and psychological interventions. *Implementation Science* 8:99. PMID: 24004579. [OA]

112. Montgomery P, Underhill K, Gardner F, Operario D, **Mayo-Wilson E** (2013). The Oxford Implementation Index: A new tool for incorporating implementation data into systematic reviews and meta-analyses. *Journal of Clinical Epidemiology* 66(8):874-882. PMID: 23810026.
113. Pilling S, **Mayo-Wilson E**, Mavranezouli I, Kew K, Taylor C, Clark DM (2013). Recognition, assessment and treatment of social anxiety disorder: Summary of NICE Guidance. *BMJ* 346:f2541. PMID: 23697669.
114. Grant SP, **Mayo-Wilson E**, Melendez-Torres G, Montgomery P (2013). Reporting quality of social and psychological intervention trials: A systematic review of reporting guidelines and trial publications. *PLOS ONE* 8(5):e65442. PMID: 23734256. [OA]
115. Stafford MR, Jackson H, **Mayo-Wilson E**, Morrison T, Kendall T (2013). Early interventions to prevent psychosis: Systematic review and meta-analysis. *BMJ* 346:f185. PMID: 23335473. [OA]
116. Strang H, Sherman LW, **Mayo-Wilson E**, Woods DJ, Ariel B (2013). Restorative Justice Conferencing (RJC) using face-to-face meetings of offenders and victims: Effects on offender recidivism and victim satisfaction. *Campbell Systematic Reviews* 9(1). DOI: 10.4073/csr.2013.12. [Published protocol] [OA]
117. Koper C, **Mayo-Wilson E** (2012). Police strategies to reduce illegal possession and carrying of firearms: Effects on gun crime. *Campbell Systematic Reviews* 8(1). DOI: 10.4073/csr.2012.11. [Published protocol] [OA]
118. Wood S, **Mayo-Wilson E** (2012). School-based mentoring for adolescents: A systematic review and meta-analysis. *Research on Social Work Practice* 22(3):257-269. DOI: 10.1177/1049731511430836. [OA]
119. **Mayo-Wilson E**, Imdad A, Herzer K, Yakoob MY, Bhutta ZA (2011). Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: Systematic review and meta-analysis. *BMJ* 343:d5094. PMID: 21868478. [Published protocol] [OA]
120. **Mayo-Wilson E**, Imdad A, Herzer K, Yakoob MY, Bhutta ZA (2011). Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age. *Journal of Evidence-Based Medicine* 4(2):141. DOI: 10.1111/j.1756-5391.2011.01129.x. [Published protocol] [OA]
121. Eysenbach G, CONSORT-EHEALTH Group [Moher D, Ritterband L, Christensen H, Stoner S, Drozd F, Blankers M, Crutzen R, Tait R, Mohr D, Evans D, Kok R, Chumnanvej S, Kooprasertying P, Anthony S, Kivuti LW, Hambly K, Aarts JW, Prins J, De la Torre I, Cook R, Jung BC, Burkhard R, Ruiz-Baques A, Gabarron E, Ahmadvand A, Gentles S, Kauer S, Kristjánsdóttir ÓB, Choubisa R, Achampong EK, Arvidsson D, Gagnon MP, Gurgan M, Daviss S, Mathieu E, Labrecque M, Anders HG, Lehto T, Kaldoudi E, Klovning A, Chih MY, Antypas K, Eide H, Lewin T, Leung FL, Ancker J, Fernando J, Archambault PM, Dias R, Lau A, Beck P, **Mayo-Wilson E**, Bewick B] (2011). CONSORT-EHEALTH: Improving and standardizing evaluation reports of Web-based and mobile health interventions. *Journal of Medical Internet Research* 13(4):e126. PMID: 22209829. [OA]
122. Imdad A, Herzer K, **Mayo-Wilson E**, Yakoob MY, Bhutta ZA (2010). Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age. *Cochrane Database of Systematic Reviews* 12:CD008524. PMID: 21154399. [Published protocol]
123. **Mayo-Wilson E**, Montgomery P, Dennis JA (2008). Personal assistance for adults (19-64) with both physical and intellectual impairments. *Cochrane Database of Systematic Reviews* 2:CD006860. PMID: 18425973. DOI: 10.1002/14651858.CD006860.pub2. [Published protocol]
124. **Mayo-Wilson E**, Montgomery P, Dennis JA (2008). Personal assistance for adults (19-64) with physical impairments. *Cochrane Database of Systematic Reviews* 3:CD006856. PMID: 18646171. [Published protocol]
125. **Mayo-Wilson E**, Montgomery P, Dennis JA (2008). Personal assistance for children and adolescents (0-18) with intellectual impairments. *Cochrane Database of Systematic Reviews* 3:CD006858. PMID: 18646172. [Published protocol]
126. **Mayo-Wilson E**, Montgomery P, Dennis JA (2008). Personal assistance for children and adolescents (0-18) with both physical and intellectual impairments. *Cochrane Database of Systematic Reviews* 3:CD006859. PMID: 18646173. [Published protocol]

127. Montgomery P, **Mayo-Wilson E**, Dennis JA (2008). Personal assistance for children and adolescents (0-18) with physical impairments. *Cochrane Database of Systematic Reviews* 3:CD006277. PMID: 18646141. [Published protocol]
128. Montgomery P, **Mayo-Wilson E**, Dennis JA (2008). Personal assistance for older adults (65+) without dementia. *Cochrane Database of Systematic Reviews* 1:CD006855. PMID: 18254118. [Published protocol]
129. **Mayo-Wilson E** (2007). Reporting implementation in randomized trials: Proposed additions to the Consolidated Standards of Reporting Trials statement. *American Journal of Public Health* 97(4):630-633. PMID: 17329641. OA
130. Koper C, **Mayo-Wilson E** (2006). Police crackdowns on illegal gun carrying: A systematic review of their impact on gun crime. *Journal of Experimental Criminology* 2(2):227-261. DOI: 10.1007/s11292-006-9005-x.
131. Renzema M, **Mayo-Wilson E** (2005). Can electronic monitoring reduce crime for moderate to high risk offenders? *Journal of Experimental Criminology* 1(2):215-237. DOI: 10.1007/s11292-005-1615-1.

Preprints not listed above

1. McKenzie JE, **Mayo-Wilson E**, Brennan SE, Hamilton DG, Takwoingi Y, Moher D, Page MJ (2026). The PRISMA family of reporting guidelines for systematic reviews: Initiatives to better support development and implementation, and future challenges and opportunities. *MetaArXiv*. DOI: 10.31222/osf.io/ydnt7_v1.
2. Goodarzi H, Pachanov A, Kugler CM, Briel M, Puljak L, Bala MM, Clarke M, **Mayo-Wilson E**, Munn Z, Pacheco RL, Norgaard B, Klugar M, Lund H, Pieper D (2026). Embedding a systematic review or meta-analysis in a randomized controlled trial article: A meta-research protocol. *OSF Preprints*. URL: https://osf.io/z9h2s/.
3. Guerra E, Menke JD, Bernabe C, Ying X, Vorland CJ, Brown AW, Qureshi R, **Mayo-Wilson E**, Kilicoglu H (2026). Automated assessment of the trustworthiness of biomedical publications: A protocol for a scoping review. *MetaArXiv*. DOI: 10.31222/osf.io/yph8c_v1.
4. Ndabashinze R, Franzen D, Kozuch E, Aagerup J, Fink A, Samruddhi YS, Hunter K, **Mayo-Wilson E**, Ying X, Kilicoglu H, Schorr SG, Seidler AL (2026). Towards understanding the disease landscape of clinical trials in Germany: Ontology and embedding-based pipelines versus large language models for ICD-10 harmonization. *medRxiv*. DOI: 10.64898/2026.08.04.26359616.
5. Naylor JA, **Mayo-Wilson E**, Martin CL, Baldwin-SoRelle C, Ranapurwala S, Canham Chervak M, Jonsson-Funk M, Marshall SW (2025). Musculoskeletal injury (MSKI) outcome definitions as reported in military population research from 2015-2025: A scoping review protocol. *OSF Preprints*. DOI: 10.31219/osf.io/nw7fy_v1.
6. Damen JAA, Snell KIE, Archer LA, Dhiman P, Trivella M, **Mayo-Wilson E**, Reitsma JB, Riley RD, Collins GS, Hooft L, Moons KGM (2024). Protocol for the development of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis of Prognostic Factor Studies (PRISMA-PF) checklist. *OSF*. URL: https://osf.io/qxke2.
7. Muran JC, Teachman B, Aldao A, Ehrenreich-May J, Fonagy P, Greenberg L, Gross J, Magnavita J, **Mayo-Wilson E**, McMain S, Soto JA, Bufka L, Halfond R, Kurtzman H, Marzalik J (2024). Proposal to Develop a Clinical Practice Guideline on Emotion Regulation: Final Report. *PsyArXiv*. DOI: 10.31234/osf.io/g627d. OA
8. Grant SP, **Mayo-Wilson E**, Supplee LH (2023). Adding standards and procedures to the What Works Clearinghouse handbook on the transparency, openness, and reproducibility of effectiveness research on education practices, products, programs, and policies. *MetaArXiv*. DOI: 10.31222/osf.io/nra5v.
9. Grant SP, **Mayo-Wilson E**, Supplee LH (2021). Adding procedures and standards to the HomVEE review handbook on the transparency, openness, and reproducibility of research on home visiting models. *MetaArXiv*. DOI: 10.31222/osf.io/7b9qj.
10. Grant SP, **Mayo-Wilson E**, Supplee LH (2021). Adding standards and procedures to the Prevention Services Clearinghouse handbook on the transparency, openness, and reproducibility of research on programs and services to enhance support for children and families and prevent foster care placements. *MetaArXiv*. DOI: 10.31222/osf.io/72mc6.

11. Helal L, da Costa GG, de Lucena CP, Luizetti BO, Freccia GW, Gonçalves LS, Nascimento DP, Rice D, **Mayo-Wilson E**, Hoffmann T (2020). Mapping outcome reporting bias in published non-pharmacological randomized trials: A protocol for a cross-sectional study. *MetaArXiv*. DOI: 10.31222/osf.io/uegmb. OA
12. Aalbersberg I, Appleyard T, Brookhart S, Carpenter T, Clarke M, Curry S, Dahl J, DeHaven A, Eich E, Franko M, Freedman L, Graf C, Grant SP, Hanson B, Joseph H, Kiermer V, Kramer B, Kraut A, Karn RK, Lee C, MacFarlane A, Martone M, **Mayo-Wilson E** (order of authorship is alphabetical), McNutt M, McPhail M, Mellor D, Moher D, Mudditt A, Nosek B, Orland B, Parker T, Parsons M, Patterson M, Santos S, Shore C, Simons D, Spellman B, Spies J, Spitzer M, Stodden V, Swaminathan S, Sweet D, Tsui A, Vazire S (2018). Making science transparent by default; Introducing the TOP statement. *OSF Preprints*. DOI: 10.17605/OSF.IO/SM78T. OA

Refereed reports

1. National Academies of Sciences, Engineering, and Medicine (2024). Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration. Washington, DC: The National Academies Press. PMID: 39312602. DOI: 10.17226/27746. OA
2. National Academies of Sciences, Engineering, and Medicine (2022). Letter report on review of Department of Veterans Affairs monograph on the economic impact and cost effectiveness of service dogs on veterans with post traumatic stress disorder. Washington, DC: The National Academies Press. DOI: 10.17226/26353. OA
3. National Academies of Sciences, Engineering, and Medicine (2021). Letter report on review of Department of Veterans Affairs monograph on potential therapeutic effects of service and emotional support dogs on veterans with post traumatic stress disorder. Washington, DC: The National Academies Press. DOI: 10.17226/26039. OA
4. Dickersin K, **Mayo-Wilson E**, Li T for the MUDS Investigators (2018). The Benefits and Challenges of Using Multiple Sources of Information about Clinical Trials. *Patient Centered Outcomes Research Institute* (peer reviewed final research report). PMID: 37043591. DOI: 10.25302/3.2018.ME.13035785. [Published protocol] OA
5. **Mayo-Wilson E**, Montgomery P, Dennis JA (2007). Umbrella Review: The effectiveness of personal support in different populations. Report to the Swedish National Board of Health and Welfare (Socialstyrelsen).

Refereed clinical practice guidelines

1. Morriss R, Kendall T, Braidwood R, Byng R, Cipriani A, James A, John C, Jones S, Legett K, Marcus E, Mavranezouli I, **Mayo-Wilson E**, McDougall T, Meyer T, Paton C, Stockton S, Schwannauer M, Swinden D, Taylor C, Westhead R, Whittington C, Wilson F (2014). Bipolar disorder: The assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. Royal College of Psychiatrists: London. PMID: 29718639. URL: https://www.nice.org.uk/guidance/cg185 OA
2. Kuipers E, Kendall T, Yesufu-Udechuku A, Slade E, Birchwood M, Brabban A, Cheema N, Green D, Harrison B, Iqbal Z, Johnson S, Marshall M, **Mayo-Wilson E**, Mitchell J, Morrison T, Moulin M, Shiers D, Stockton S, Taylor C, Travis C, Waddingham R, Woodhams P, Young N (2014). Psychosis and Schizophrenia in Adults: The NICE guideline on the treatment and management of psychosis and schizophrenia in adults. Royal College of Psychiatrists: London. PMID: 25340235. URL: https://www.nice.org.uk/guidance/cg178 OA
3. Clark DM, Pilling S, **Mayo-Wilson E**, Mavranezouli I, Afghan S, Anigbogu B, Armstrong P, Bennett M, Cartwright-Hatton S, Creswell C, Dix M, Hanlon N, Kew K, Leggett K, Malizia A, Roberts J, Satrettin K, Smith M, Stephens G, Stopa L, Stockton S, Taylor C, Whittington C (2013). Social anxiety disorder: The NICE guideline on the recognition, assessment and treatment of social anxiety disorder. Royal College of Psychiatrists: London. PMID: 25577940. URL: https://www.nice.org.uk/guidance/cg159 OA

Refereed commentaries and editorials

1. Ying X, **Mayo-Wilson E** (2026). Outcome reporting in cohort studies of interventions. *BMJ* 393:s922. PMID: 42203256.

2. Moher D, Page M, McKenzie J, Takwoingi Y, **Mayo-Wilson E** (2026). PRISMA-trAIce: A Name Without Endorsement. *JMIR AI* 5:e104210. PMID: 42612062.
3. Christensen R, Berthelsen DB, Tugwell P, Golder S, Qureshi R, **Mayo-Wilson E**, Simon LS, Kwong J, Williamson PR, Vohra S (2026). Harm outcomes applicable for most meta-analyses of randomized trials of biomedical interventions: A key concept in clinical epidemiology. *Journal of Clinical Epidemiology* 194:112218. PMID: 41802580.
4. Puljak L, Munn Z, Pieper D, Marušić A, Collins G, Naudet F, **Mayo-Wilson E**, Hooft L, van der Braak K, Lund H (2026). A call for action: ICMJE should require mandatory prospective registration of systematic reviews. *Journal of Clinical Epidemiology*. In press.
5. **Mayo-Wilson E** (2025). Complete reporting of clinical trials requires more than journal articles. *BMJ* 389:r494. PMID: 40228826. [OA]
6. Li T, **Mayo-Wilson E**, Shaughnessy D, Qureshi R (2024). Studying harms of interventions with an equity lens in randomized trials. *Trials* 25(1):403. PMID: 38902776.
7. **Mayo-Wilson E**, Qureshi R, Li T (2023). Conducting separate reviews of benefits and harms could improve systematic reviews and meta-analyses. *Systematic Reviews* 12(1):67. PMID: 37061724.
8. Brown A, Aslibekyan S, Bier D, Ferreira Da Silva R, Hoover A, Klurfeld DM, Loken E, **Mayo-Wilson E**, Menachemi N, Pavela G, Quinn PD, Schoeller D, Tekwe C, Valdez D, Vorland CJ, Whigham LD, Allison DB (2023). Toward more rigorous and informative nutritional epidemiology: The rational space between dismissal and defense of the status quo. *Critical Reviews in Food Science and Nutrition* 63(18):3150-3167. PMID: 34678079.
9. Chevance AMC, Ravaud P, Cornelius V, **Mayo-Wilson E**, Furukawa T (2022). Designing clinically useful psychopharmacological trials: Challenges and ways forward. *The Lancet Psychiatry* 9(7):584-594. PMID: 35525252.
10. Hansford HJ, Cashin AG, Wewege MA, Ferraro MC, McAuley JH, Jones MD, and the **TOP Sport Science Collaborators [contributor]** (2022). Open and transparent sports science research: The role of journals to move the field forward. *Knee Surgery, Sports Traumatology, Arthroscopy* 30(11):3599-3601. PMID: 35092443. [OA]
11. **Mayo-Wilson E** (2021). Should e-cigarette regulation be based on randomized trials or observational studies? *American Journal of Public Health* 111(2):219-220. PMID: 33439718. [OA]
12. Vorland CJ, Brown AW, Ejima K, **Mayo-Wilson E**, Valdez D, Allison DB (2020). Toward fulfilling the aspirational goal of science as self-correcting: A call for editorial courage and diligence for error correction. *European Journal of Clinical Investigation* 50(2):e13190. PMID: 31788792.
13. Valdez D, Vorland CJ, Brown AW, **Mayo-Wilson E**, Otten J, Ball R, Grant S, Levy R, Valdivia DS, Allison DB (2020). Improving open and rigorous science: Ten key future research opportunities related to rigor, reproducibility, and transparency in scientific research. *F1000Research* 9:1235. PMID: 33628434. [OA]
14. **Mayo-Wilson E**, Dickersin K (2018). Challenges stemming from NIH's extended registration and reporting requirements. *Nature Human Behaviour* 2(2):97. DOI: 10.1038/s41562-017-0286-z.
15. McLeroy K, Garney W, **Mayo-Wilson E**, Grant SP (2016). Scientific reporting: Raising the standards. *Health Education & Behavior* 43(5):501-508. PMID: 27624441.

Other commentaries and editorials

1. Tanner-Smith E, Grant S, **Mayo-Wilson E** (2022). Modern Meta-Analytic Methods in Prevention Science: Introduction to the Special Issue. *Prevention Science* 23(3):341-345. PMID: 35171463.

Letters

1. Hansford HJ, Cashin AG, Wewege MA, Ferraro MC, McAuley JH, Jones MD, and the **TOP Sport Science Collaborators [contributor]** (2022). Evaluation of journal policies to increase promotion of transparency and openness in sport science research. *Journal of Science and Medicine in Sport* 25(2):192-194. PMID: 34474960.
2. Hansford HJ, Cashin AG, Wewege MA, Ferraro MC, McAuley JH, Jones MD, and the **TOP Sport Science Collaborators [contributor]** (2021). Evaluation of journal policies to increase promotion of transparency and openness in sport science research. *Arthroscopy* 37(11):3223-3225. PMID: 34740399. [OA]

3. Vorland CJ, Foote G, Dickinson SL, **Mayo-Wilson E**, Allison DB, Brown AW (2020). Letter to the Editor regarding Abdelbasset, W. K., Tantawy, S. A., Kamel, D. M., Alqahtani, B. A., Elnegamy, T. E., Soliman, G. S., & Ibrahim, A. A. (2020). Effects of high-intensity interval and moderate-intensity continuous aerobic exercise on diabetic obese patients with nonalcoholic fatty liver disease: A comparative randomized controlled trial. Medicine (correspondence blog).
4. Appelbaum M, Cooper H, Kline R, **Mayo-Wilson E** (order of authorship is alphabetical), Nezu AM, Rao S (2018). Intent of Reporting Standards: Reply to Rossiter (2018). *American Psychologist* 73(7):932. PMID: 30284892.
5. **Mayo-Wilson E**, Grant SP, Montgomery P (2017). A framework to describe intervention implementation (design, delivery, uptake, and context) in systematic reviews. Response to Hoffmann T, Oxman AD, Ioannidis JPA, Moher D, Lasserson TJ, Tovey DI, Stein K, Sutcliffe K, Ravaud P, Altman DG, Perera R, Glasziou P (2017) Enhancing the usability of systematic reviews by improving the consideration and description of interventions. *BMJ* 358:j2998. URL: https://www.bmj.com/content/358/bmj.j2998/rr-0.
6. **Mayo-Wilson E**, Dickersin K (2017). Does transparency in theory lead to transparency in practice? Response to Goldacre B, Lane S, Mahtani K, Heneghan C, Onakpoya I, Bushfield I, Smeeth L (2017) Pharmaceutical companies' policies on access to trial data, results, and methods: Audit study. *BMJ* 358:j3334. URL: https://www.bmj.com/content/358/bmj.j3334/rr-0.
7. Grant SP, **Mayo-Wilson E**, Montgomery P (2016). Implementing Quality Improvement for Psychosocial Interventions. *JAMA* 315(9):943. PMID: 26934268.
8. Morriss R, **Mayo-Wilson E**, Kendall T (2016). NICE guidance: Why not clozapine for treatment refractory bipolar disorder? (Authors' reply). *The Lancet Psychiatry* 3(6):503. PMID: 27262048.
9. Kendall T, Morriss R, **Mayo-Wilson E**, Meyer TD, Jones SH, Oud M, Baker MR (2016). NICE guidance on psychological treatments for bipolar disorder (Authors' reply). *The Lancet Psychiatry* 3(4):317-320. PMID: 27063379.
10. **Mayo-Wilson E**, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, Pilling S (2015). Heightened risk of false positives in a network meta-analysis of social anxiety – Author's reply. *The Lancet Psychiatry* 2(4):293-294. PMID: 26360072.
11. Hofmann SG, Barlow DH, Clark DM, Hollon SD, **Mayo-Wilson E** (2015). Treatments for Social Anxiety Disorder: Considerations Regarding Psychodynamic Therapy Findings. *American Journal of Psychiatry* 172(4):393. PMID: 25827035.
12. **Mayo-Wilson E**, Imdad A, Herzer K, Bhutta ZA (2013). Vitamin A supplementation in Indian children. *The Lancet* 382(9892):594. PMID: 23953382.
13. **Mayo-Wilson E**, Montgomery P, Hopewell S, Macdonald G, Moher D, Grant SP (2013). Developing a reporting guideline for social and psychological intervention trials. *British Journal of Psychiatry* 203(3):250-254. PMID: 24029534. [OA]
14. **Mayo-Wilson E** (2013). Apparent Discrepancy Between Published Study of Gabapentin Treatment and Internal Company Report. *Journal of Clinical Psychiatry* 74(8):853-854. PMID: 24021509.
15. **Mayo-Wilson E**, Grant SP, Hopewell S, Macdonald G, Moher D, Montgomery P (2013). Developing a reporting guideline for social and psychological intervention trials. *Trials* 14:242. PMID: 23915044. [OA]
16. Montgomery P, Grant SP, Hopewell S, Macdonald G, Moher D, **Mayo-Wilson E** (2013). Developing a reporting guideline for social and psychological intervention trials. *British Journal of Social Work* 43(5):1024-1038. DOI: 10.1093/bjsw/bct129.
17. Grant SP, Montgomery P, Hopewell S, Macdonald G, Moher D, **Mayo-Wilson E** (2013). Developing a reporting guideline for social and psychological intervention trials. *Research on Social Work Practice* 23(6):595-602. PMID: 25076832.
18. Gardner F, **Mayo-Wilson E**, Montgomery P, Hopewell S, Macdonald G, Moher D, Grant SP (2013). The need for new guidelines to improve the reporting of trials in child and adolescent mental health. *Journal of Child Psychology and Psychiatry* 54(7):810-812. PMID: 23789914.
19. Grant SP, **Mayo-Wilson E**, Hopewell S, Macdonald G, Moher D, Montgomery P (2013). New guidelines are needed to improve the reporting of trials in addiction sciences. *Addiction* 108(9):1687-1688. PMID: 23796394.

20. Montgomery P, **Mayo-Wilson E**, Hopewell S, Macdonald G, Moher D, Grant SP (2013). Developing a reporting guideline for social and psychological intervention trials. *American Journal of Public Health* 103(10):1741-1746. PMID: 23947317.
21. Grant SP, **Mayo-Wilson E**, Hopewell S, Macdonald G, Moher D, Montgomery P (2013). Developing a reporting guideline for social and psychological intervention trials. *Journal of Experimental Criminology* 9(3):355-367. DOI: 10.1007/s11292-013-9180-5.
22. **Mayo-Wilson E**, Imdad A, Herzer K, Bhutta ZA (2012). There is no need for further placebo controlled trials. Response to: Fisker AB, *et al*. Does the effect of vitamin A supplements depend on vaccination status? An observational study from Guinea-Bissau. *BMJ Open* 2(1):e000448. URL: https://bmjopen.bmj.com/content/2/1/e000448.responses#there-is-no-need-for-further-placebo-controlled-trials.
23. Grant SP, Montgomery P, **Mayo-Wilson E** (2012). Development of a CONSORT extension for interventions in public health and related disciplines. *The Lancet* 380:S14. DOI: 10.1016/S0140-6736(13)60370-0.
24. **Mayo-Wilson E** (2007). Internet-based cognitive behaviour therapy for symptoms of depression and anxiety: A meta-analysis. *Psychological Medicine* 37(8):1211. PMID: 17717855.
25. **Mayo-Wilson E** (2006). Health care interventions delivered over the internet: How systematic was the review? *Journal of Medical Internet Research* 8(2):e11. PMID: 16867966.

Blog posts

1. **Mayo-Wilson E** (2020). Featured Guest Post: What makes a reliable systematic review and meta-analysis? Department of Veterans Affairs Evidence Synthesis Program. URL: https://mfr.osf.io/render?url=https://osf.io/jt4xc/?direct%26mode=render%26action=download%26mode=render
2. Montgomery P, **Mayo-Wilson E**, Grant S (2018). CONSORT-SPI 2018: Announcing an extension for randomised controlled trials of social and psychological interventions. *On Medicine* (BMC blog). URL: http://blogs.biomedcentral.com/on-medicine/2018/07/31/consort-spi-2018-announcing-an-extension-for-randomized-controlled-trials-of-social-and-psychological-interventions/

Newspaper and magazine articles

1. **Mayo-Wilson E**, Grant SP, Montgomery P (2014). "Do preventive home visits work?" *The Guardian*. April 7, 2014. https://www.theguardian.com/social-care-network/2014/apr/07/do-preventive-home-visits-work
2. Pilling S, Taylor C, **Mayo-Wilson E**, Clark DM (2013). Flexible access to services is needed for social anxiety disorder. *Guidelines in Practice* 16(8):29-36.

ORAL PRESENTATIONS

International

1. **Mayo-Wilson E**. AI tools for reporting guidelines. Invited oral presentation at CONSORT Symposium: Celebrating 30 Years of CONSORT: Future Directions in Trial Reporting. Virtual event. November 10, 2026.
2. **Mayo-Wilson E**. Using artificial intelligence to detect changes in clinical trial outcomes. Invited oral presentation at Evolving Methods for Evidence Synthesis of Health Research Symposium, Monash University. Melbourne, Australia. February 6, 2025.
3. **Mayo-Wilson E**. A brief history of clinical trial registration. Session chair and invited oral presentation at The Promises and Pitfalls of Preregistration, The Royal Society. London, UK. March 4, 2024.
4. **Mayo-Wilson E**. Applying lessons from regulatory research to assessing harms in behavioral interventions. Invited oral presentation at MRC-NIHR Trials Methodology Research Partnership (TMRP) Adverse Events in Clinical Trials Working Group. Virtual event. September 30, 2022.
5. **Mayo-Wilson E**. Summaries of harms in systematic reviews are unreliable. Invited oral presentation at Methods Speaker Series, St Michael's Hospital, Unity Health Toronto (University of Toronto). Virtual event. April 27, 2022.

6. **Mayo-Wilson E**. Cherry picking results: Effects on clinical trial reports and systematic reviews. Invited oral presentation at David Moher Cochrane Methods Symposium: Bias and Beyond. Edinburgh, UK. September 15, 2018.
7. **Mayo-Wilson E**. Registering, reporting, and reviewing social intervention trials to inform policy and practice. Oral presentation at What Works Global Summit. London, UK. September 26-28, 2016.
8. **Mayo-Wilson E**, Grant SP, Cybulski L, Montgomery P. Improving transparency and reducing waste beyond biomedicine. Oral presentation at REWARD/EQUATOR Conference, Edinburgh, UK. September 28-30, 2015.
9. **Mayo-Wilson E**, Fusco N, Gresham G, Ehmsen J, Heyward J, Lock D, Suarez-Cuervo C, Hutfless S, Li T, Dickersin K. Wasted results: Multiplicity in outcome definitions is a mechanism for reporting bias. Oral presentation at REWARD/EQUATOR Conference, Edinburgh, UK. September 28-30, 2015.
10. **Mayo-Wilson E** on behalf of The Transparency and Openness Promotion (TOP) Committee. The TOP guideline to promote transparency, openness, and reproducibility. Oral presentation at REWARD/EQUATOR Conference, Edinburgh, UK. September 28-30, 2015.
11. **Mayo-Wilson E**. Engaging with guideline producers. Invited oral presentation at Cochrane UK & Ireland 21st Anniversary Symposium. Oxford, UK. March 21, 2013.
12. Montgomery P, **Mayo-Wilson E** (co-presenters). Reporting guidelines for implementation data in systematic reviews: First consensus meeting. Workshop at Cochrane and Campbell Collaborations Colloquium, Keystone, CO. October 18-22, 2010.
13. **Mayo-Wilson E**. Self-help for anxiety. Invited oral presentation at Louis and Gaby Weisfeld School of Social Work, Bar Ilan University. Tel Aviv, Israel. June 24, 2010.
14. Underhill K, **Mayo-Wilson E**, Gardner F, Operario D, Montgomery P (co-presenters). A new tool to incorporate implementation data into systematic reviews: Applying the Oxford Implementation Index. Workshop at Cochrane Colloquium, Dublin, Ireland. October 23-26, 2006.
15. **Mayo-Wilson E**. Electronic monitoring: Widely applied, poorly understood. Oral presentation at Campbell Colloquium on Systematic Reviews and Meta-Analysis, Lisbon, Portugal. February 23-25, 2005.

National

While working in the US

1. **Mayo-Wilson E**. Harms in systematic reviews of interventions. Invited presentation to the National Academies of Sciences, Engineering, and Medicine panel *Finding What Works in Health Care: Updating Standards for Systematic Reviews*. Virtual event. February 27, 2026.
2. **Mayo-Wilson E**, Ying X (co-presenters). Using artificial intelligence to improve clinical trials and to identify changes in outcomes. Invited oral presentation at Center for Clinical Trials and Evidence Synthesis Seminar, Johns Hopkins Bloomberg School of Public Health. Virtual event. December 5, 2025.
3. **Mayo-Wilson E**. Do we need science culture change or just a change to our tools? Invited oral presentation at Biomedical Transparency Summit (BMTS 2023). Washington, DC. June 9, 2023.
4. Grant S, **Mayo-Wilson E** (co-presenters). Implementation of open science standards in the evidence ecosystem for social and behavioral interventions. Invited oral presentation at METRICS International Forum, Stanford University. Virtual event. March 9, 2023.
5. Qureshi R, **Mayo-Wilson E**, Pieper D (co-presenters), Vohra S (discussant). Compounding complications: Synthesizing harms across the evidence pipeline. Symposium at Society for Research Synthesis Methodology. Portland, OR. July 19, 2022.
6. Grant S, **Mayo-Wilson E**, Naaman K (co-presenters), Tanner-Smith E (discussant). Implementation of open science standards in the evidence ecosystem for social and behavioral interventions. Symposium at Society for Research Synthesis Methodology. Portland, OR. July 19, 2022.
7. **Mayo-Wilson E**. Synthesizing evidence about harms in systematic reviews. Invited oral presentation at Department of Internal Medicine, The Ohio State University College of Medicine. Virtual event. November 22, 2021.
8. **Mayo-Wilson E** (chair), Grant S, Kianersi S, Naaman K, Supplee L (co-presenters). Incorporating open science into evidence-based practice: The TRUST Initiative. Symposium at Metascience 2021. Virtual event. September 17, 2021.

9. **Mayo-Wilson E**. Synthesizing harms of interventions: Harms data collection and grouping. Invited oral presentation at AHRQ Methods Symposium: Advanced Methods and Innovative Technologies for Evidence Synthesis. Virtual event. March 8, 2021.
10. **Mayo-Wilson E**. PRISMA 2020: Updated guidance for reporting systematic reviews of interventions. Invited oral presentation at Department of Veterans Affairs Evidence Synthesis Program Coordinating Center. Virtual event. December 9, 2020.
11. **Mayo-Wilson E**. Multiple outcomes in clinical trials and systematic reviews. Invited oral presentation at Neuroscience seminar on Alzheimer's Talks, The University of Texas Rio Grande Valley. Virtual event. January 9, 2019.
12. **Mayo-Wilson E**. Evaluating the efficacy of behavioral interventions and the prospects for improvement. Invited oral presentation at Behavioral Medicine Research Council Founding Conference. Washington, DC. December 10-11, 2018.
13. **Mayo-Wilson E**. Challenges associated with multiple outcome definitions in clinical research. Invited oral presentation at National Institutes of Health Mind the Gap Webinar Series. Virtual event. November 27, 2018.
14. **Mayo-Wilson E**. Assessing and reporting adverse events. Invited oral presentation at University of Iowa Department of Biostatistics Seminar Series. Iowa City, Iowa. November 13, 2018.
15. **Mayo-Wilson E**. Increasing trust in clinical trials. Invited oral presentation at University of Iowa Department of Biostatistics Seminar Series. Iowa City, Iowa. November 12, 2018.
16. **Mayo-Wilson E**. Increasing trust in public health research. Invited oral presentation at Indiana University School of Public Health-Bloomington, Department of Epidemiology and Biostatistics. Bloomington, IN. September 27, 2018.
17. **Mayo-Wilson E**. APA reporting standards for quantitative and qualitative research—increasing transparency. Oral presentation at American Psychological Association Convention. San Francisco, CA. August 11, 2018.
18. **Mayo-Wilson E**, Grant S, Gardner F (co-presenters). Research transparency, openness, and reproducibility. Brown bag special interest group at Society for Prevention Research. Washington, DC. May 31, 2018.
19. **Mayo-Wilson E**. Increasing compliance with clinical trial reporting requirements at academic medical centers. Invited oral presentation at Center for Excellence in Regulatory Science and Innovation Meeting, US Food and Drug Administration. Silver Spring, MD. July 26, 2017.
20. **Mayo-Wilson E**. Comparator group selection in behavioral and social science clinical trials. Invited oral presentation at National Institutes of Health Office of Behavioral and Social Sciences Research (OBSSR) Working Group. Bethesda, MD. April 13, 2017.
21. **Mayo-Wilson E**. Measuring harms that matter to patients in clinical trials. Invited oral presentation at Center for Excellence in Regulatory Science and Innovation Seminar Series, US Food and Drug Administration. Silver Spring, MD. June 22, 2016.
22. **Mayo-Wilson E**. Choosing outcomes that are appropriate across a population: Deliberative approaches. Invited oral presentation at Assessing Safety and Efficacy for a Diverse Population, US Food and Drug Administration. Silver Spring, MD. December 2, 2015.
23. **Mayo-Wilson E** (presenter), Grant SP, Montgomery P, McLeroy K. Reporting guideline for trials of social and psychological interventions: CONSORT-SPI. Oral presentation at APHA Annual Meeting and Exposition, New Orleans, LA. November 17, 2014.
24. **Mayo-Wilson E**. Core outcome sets for patient-centered outcomes research. Invited oral presentation at RAND, Corp., Santa Monica, CA. October 10, 2014.
25. **Mayo-Wilson E** (presenter), Grant SP, Montgomery P. Reporting randomized controlled trials in education. Oral presentation at Society for Research on Educational Effectiveness, Washington, DC. September 4, 2014.
26. **Mayo-Wilson E** (presenter), Grant SP, Montgomery P. A reporting guideline for trials of social and psychological interventions: CONSORT-SPI. Oral presentation at American Psychological Association, Washington, DC. August 8, 2014.
27. **Mayo-Wilson E**. Increasing capacity for reviewing: From training to publication of reviews. Oral presentation at Campbell Colloquium on Systematic Reviews and Meta-Analysis, Los Angeles, CA. February 22-24, 2006.

While working in the UK

28. **Mayo-Wilson E**. Using meta-analysis to determine efficacy. Invited oral presentation at London Central Local Pharmacy Forum. London, UK. November 12, 2013.
29. **Mayo-Wilson E**. Investigating complex interventions. Invited oral presentation at Breathlessness Research Interest Group. Institute of Public Health, University of Cambridge. Cambridge, UK. June 7, 2013.

Local

While working in the US

1. **Mayo-Wilson E**. Assessing harms in systematic reviews. Invited oral presentation at DUK-RTI-UNC Methods Seminar. Virtual event. June 15, 2023.
2. **Mayo-Wilson E**. Synthesizing evidence about harms. Oral presentation at AHRQ T32 Seminar Series. Sheps Center for Health Services Research, NC. November 7, 2022.
3. **Mayo-Wilson E**. Multiplicity and reporting in clinical trials and systematic reviews. Oral presentation at UNC Pharmacoepidemiology Seminar Series. UNC Gillings School of Global Public Health, NC. September 19, 2022.
4. **Mayo-Wilson E**. Synthesizing evidence about harms in systematic reviews. Oral presentation at UNC Gillings School of Global Public Health. Chapel Hill, NC. November 19, 2021.
5. **Mayo-Wilson E**. Multiplicity in systematic reviews and meta-analysis: Dealing with multiple sources and multiple outcomes. Oral presentation at Workshop in Methods. Indiana University-Bloomington, IN. February 21, 2020.
6. **Mayo-Wilson E**, Li T (co-presenters). Benefits and challenges of using multiple data sources in systematic reviews. Oral presentation at Evidence Practice Center Journal Club, Center for Health Services and Outcomes Research Seminar Series, Johns Hopkins Bloomberg School of Public Health. Baltimore, MD. November 20, 2019.
7. **Mayo-Wilson E**. Defining and reporting adverse events. Oral presentation at Clinical Research Grand Rounds. Johns Hopkins Welch Center for Prevention, Epidemiology and Clinical Research. March 7, 2018.
8. **Mayo-Wilson E**, Li T. Access to multiple reports of clinical trials: Problems or solutions? Oral presentation at Center for Clinical Trials and Evidence Synthesis Seminar Series, Johns Hopkins Bloomberg School of Public Health. Baltimore, MD. September 8, 2016.
9. **Mayo-Wilson E** (presenter), Dickersin K. Open access to trials: Will it give us all that we need? Oral presentation at Center for Drug Safety and Effectiveness Seminar Series, Johns Hopkins Bloomberg School of Public Health. Baltimore, MD. October 19, 2015.
10. **Mayo-Wilson E**. Interventions for social anxiety disorder. Oral presentation at Center for Health Services and Outcomes Research, Johns Hopkins Bloomberg School of Public Health. Baltimore, MD. November 11, 2014.
11. **Mayo-Wilson E**. Patient-centered outcomes and evidence synthesis. Oral presentation at Center for Clinical Trials and Evidence Synthesis Seminar Series, Johns Hopkins Bloomberg School of Public Health. Baltimore, MD. November 5, 2014.

While working in the UK

12. **Mayo-Wilson E**. Self-help for anxiety disorders. Invited oral presentation at Camden and Islington Improving Access to Psychological Therapies (IAPT) Research Meeting. London, UK. June 1, 2011.
13. **Mayo-Wilson E**, Montgomery P. Self-help for anxiety. Oral presentation at Oxford Student Mental Health Network. Oxford, UK. May 30, 2008.
14. **Mayo-Wilson E**, Montgomery P. Anxiety in primary care. Invited oral presentation at Primary Care Psychiatry Workshop. London, UK. May 16, 2006.

POSTERS AND CO-AUTHORED PRESENTATIONS

International

1. Goodarzi H, Pachanov A, Kugler CM, Briel M, Puljak L, Bala MM, Clarke M, **Mayo-Wilson E**, Munn Z, Pacheco RL, Norgaard B, Klugar M, Lund H, Pieper D. Embedding a systematic review or meta-analysis in a report of a randomized controlled trial: A meta-research study. Abstract submitted to the 28th Annual Meeting of the German Network for Evidence-Based Medicine (EbM-Kongress 2027). Halle (Saale), Germany. March 10-12, 2027.

2. Zeng M, Clark DPQ, Nussbaumer-Streit B, Hamilton DG, Nguyen P, **Mayo-Wilson E**, Ying X, Kilicoglu H, McKenzie JE, Page MJ (presenter). Large language models for automating assessments of adherence to the PRISMA 2020 statement. Accepted for oral presentation at the Cochrane Colloquium. Kraków, Poland. December 10, 2026.
3. Todhunter-Brown A, Petkovic J, Chang C, Griebler U, Hannigan A, Hilgart J, Hussain B, Jull J, Koscher-Kien C, Ledinger D (presenter), Nussbaumer-Streit B, Oloyede O, Tomlinson E, Dawson S, Dewidar O, Grant S, Lytvyn L, Concannon TW, Dans L, John D, Jordan Z, **Mayo-Wilson E**, McCutcheon C, Nonino F, Pollock D, Toupin April K, Campbell P, Khabsa J, Magwood O, Welch V, Tugwell P. How are interest-holders involved in evidence syntheses? Results from a scoping review. Accepted for oral presentation at the Cochrane Colloquium. Kraków, Poland. December 9, 2026.
4. Goodarzi H (presenter), Pachanov A, Kugler CM, Briel M, Puljak L, Bala MM, Clarke M, **Mayo-Wilson E**, Munn Z, Pacheco RL, Norgaard B, Klugar M, Lund H, Pieper D. Embedding a systematic review or meta-analysis in a report of a randomized controlled trial: A meta-research study. Oral presentation at the 6th Evidence-Based Research Conference. Virtual event. October 13-16, 2026.
5. Das P (presenter), **Mayo-Wilson E**, Kilicoglu H, Smalheiser N, Schneider J. Bridging gaps between study designs and knowledge claims. Oral presentation at Mobilizing Computable Biomedical Knowledge (MCBK) 2026 Global Meeting. Virtual event. October 13-14, 2026.
6. Guerra E (presenter), Menke J, Vorland CJ, **Mayo-Wilson E**, Kilicoglu H. AI-assisted rigor assessment in published biomedical research: A scoping review of variability in definitions and generalizability. Oral presentation at World Conference on Research Integrity. Vancouver, BC, Canada. May 3-6, 2026.
7. Grant S (presenter), **Mayo-Wilson E**, Supplee L. Do "evidence-based" interventions need to be based on open science? An analysis of clearinghouse standards. Oral presentation at 35th Annual Conference of the European Health Psychology Society. Virtual event. August 23, 2021.
8. **Mayo-Wilson E** (presenter), Heyward J, Keyes A, Reynolds J, White S, Atri N, Alexander C, Omar A, Ford DE. Supporting clinical trial registration and reporting requirements at academic organizations in the USA. Poster at Cochrane Colloquium. Edinburgh, UK. September 16-18, 2018.
9. Fusco N (presenter), Dickersin K, Scherer RW, Bertizzolo L, Saldanha I, Vedula SS, Li T, **Mayo-Wilson E**. The pros and cons of including abstracts in systematic reviews: Findings from the Multiple Data Sources Study (MUDS). Poster at Cochrane Colloquium. Seoul, South Korea. October 23-27, 2016.
10. Fusco N (presenter), **Mayo-Wilson E**, Li T, Dickersin K. Do multiple data sources about a single trial agree on risk of bias and PICO (participant, intervention, comparator, outcome) information? Oral presentation at Cochrane Colloquium. Seoul, South Korea. October 23-27, 2016.
11. Fusco N (presenter), **Mayo-Wilson E**, Li T, Dickersin K. Evidence that multiplicity in outcome definitions could introduce selective outcome reporting. Poster at Cochrane Colloquium. Seoul, South Korea. October 23-27, 2016.
12. Li T (presenter), Hong H, Fusco N, **Mayo-Wilson E**, Dickersin K. Too much data from too many sources: What is the best estimate of the treatment effect? Oral presentation at Cochrane Colloquium. Seoul, South Korea. October 23-27, 2016.
13. Li T (presenter), Hong H, Fusco N, **Mayo-Wilson E**, Dickersin K. Too much data from too many sources: What is the best estimate of the treatment effect? Oral presentation at Society for Research Synthesis Methodology Annual Meeting. Florence, Italy. July 3-5, 2016.
14. **Mayo-Wilson E** (presenter), Montgomery P. Missing data in systematic reviews: A table might help. Poster at Joint Colloquium of the Cochrane & Campbell Collaborations, Keystone, CO. October 18-22, 2010.
15. Koper C (presenter), **Mayo-Wilson E**. Police crackdowns on illegal gun carrying: A systematic review for the Campbell Collaboration Crime and Justice Group. Oral presentation at Stockholm Criminology Symposium, Stockholm, Sweden. June 15-17, 2006.

16. Montgomery P (presenter), Gardner F, Operario D, **Mayo-Wilson E**, Tamayo S, Underhill K. The Oxford Implementation Reporting Index: The development of an indicator of treatment fidelity in systematic reviews of psycho-social interventions. Poster at Cochrane Colloquium, Melbourne, Australia. October 22-26, 2005.

National

While working in the US

1. Ismail S (presenter), Jonsson Funk M, Flythe JE, Edwards J, Stürmer T, Kotzen E, **Mayo-Wilson E**. Comparative effectiveness and harms of belatacept versus tacrolimus among kidney transplant recipients. Poster at American Society of Nephrology Kidney Week 2026. Denver, CO. October 22-25, 2026.
2. Ying X (presenter), Vorland C, Ninan K, Oberste JP, Brown A, Qureshi R, Zhang S, DeVito N, Page M, Saldanha I, Kilicoglu H, **Mayo-Wilson E**. Using GPT to identify changes in clinical trial outcomes registered on ClinicalTrials.gov. Plenary session at International Congress on Peer Review and Scientific Publication. Chicago, IL. September 5, 2025.
3. Jiang L (presenter), Ying X, Lan M, Brown A, Vorland C, **Mayo-Wilson E**, Kilicoglu H. Leveraging large language models for assessing the adherence of randomized controlled trial publications to reporting guidelines. Plenary session at International Congress on Peer Review and Scientific Publication. Chicago, IL. September 5, 2025.
4. Ismail S (presenter), Kotzen E, Flythe J, Edwards J, Stürmer T, Jonsson Funk M, **Mayo-Wilson E**. Use of belatacept and tacrolimus among kidney transplant recipients from 2011-2020: Comparing United States Renal Data System (USRDS) and Scientific Registry of Transplant Recipients (SRTR). Poster at International Society for Pharmacoepidemiology (ISPE). Washington, DC. August 22-26, 2025.
5. Ismail S (presenter), Kotzen E, Flythe J, Edwards J, Stürmer T, Jonsson Funk M, **Mayo-Wilson E**. Belatacept use among U.S. kidney transplant recipients (2011-2020). Poster at International Society for Pharmacoepidemiology (ISPE). Washington, DC. August 22-26, 2025.
6. **Mayo-Wilson E** (presenter), Vander Ley K, Dickersin K, Helfand M. Patient-Centered Outcomes Research Institute (PCORI) methodology standards to improve the design and reporting of research. Poster at Peer Review Congress. Chicago, IL. September 10-12, 2017.
7. Sox H (presenter), **Mayo-Wilson E**, Helfand M, Vander Ley K, Broitman M, Hickam D, Clauser S, Chiang Y, Whitlock E. Scientific quality in a series of comparative effectiveness research studies. Oral presentation at Peer Review Congress. Chicago, IL. September 10-12, 2017.
8. Renzema M (presenter), **Mayo-Wilson E**. Electronic monitoring's impact: A meta-analysis. Oral presentation at Annual Meeting of the Academy of Criminal Justice Sciences, Chicago, IL. March 16-19, 2005.

While working in the UK

9. Clark DM (presenter), **Mayo-Wilson E**, Pilling S, Hanlon N, Stephens G, Stopa L, Creswell C, Cartwright-Hatton S. The new NICE guideline for the assessment and treatment of social anxiety disorder. Symposium at British Association for Behavioural and Cognitive Psychotherapies, London, UK. July 17-19, 2013.
10. **Mayo-Wilson E** (presenter), Montgomery P. A systematic review of self-help for anxiety. Poster at British Association for Behavioural and Cognitive Psychotherapies Annual Conference. Warwick, UK. July 19-21, 2006.

COURSES TAUGHT

UNC Gillings School of Global Public Health

Pharmacoepidemiology Seminar (EPID 893) — Fall 2026—present
Sole instructor (100%) — Enrollment: 9, Credits: 1

Epidemiologic Research Methods (EPID 726, required) — Fall 2026—present
Small group instructor — Small group: 6, Credits: 3

Systematic Review (EPID 702) — Spring 2024—present
Lead instructor with Cindy Feltner (50%), Spring 2024, 2025 — Enrollment: 29 (2025), Credits: 2
Sole instructor (100%), Spring 2026—present — Enrollment: 21, Credits: 2

Indiana University School of Public Health-Bloomington

Intermediate Epidemiology (SPH-E 658, required) — Spring 2020—2022
Sole instructor (100%) — Enrollment: 20, Credits: 3

Meta-Analysis and Systematic Reviews (SPH-E 670) — Fall 2020
Sole instructor (100%) — Enrollment: 15, Credits: 3

Johns Hopkins Bloomberg School of Public Health

Methods for Conducting Systematic Reviews and Meta-Analyses (340.606.01) — 3rd term 2019
Lead instructor with Tianjing Li (50%) — Enrollment: 50, Credits: 4

Clinical Trials: Procedures, Design, and Interpretation of Results (340.861.81) — 3rd term 2016—2019
Lead instructor with Janet Holbrook (50%) — Enrollment: 45, Credits: 3

Introduction to Clinical Trials (340.645.81, online) — 1st term 2015—2017, 2nd term 2018
Lead instructor with Janet Holbrook (50%) — Enrollment: 100, Credits: 3

Introduction to Clinical Trials (340.645.01, in-person) — 2nd term 2016—2017
Lead instructor with Janet Holbrook (50%) — Enrollment: 50, Credits: 3

University of Oxford

Systematic Reviews II — 3rd term 2008—2011
Sole instructor (100%) — Enrollment: 20, Credit equivalent: 3

Systematic Reviews I — 2nd term 2008—2011
Sole instructor (100%) — Enrollment: 20, Credit equivalent: 3

Research Methods in Evidence-Based Social Intervention II (required) — 2nd term 2008—2011
Lead instructor with Paul Montgomery (50%) — Enrollment: 35, Credit equivalent: 3

Research Methods in Evidence-Based Social Intervention I (required) — 1st term 2007—2010
Lead instructor with Paul Montgomery (50%) — Enrollment: 35, Credit equivalent: 3

OTHER SUPERVISED RESEARCH

Indiana University School of Public Health-Bloomington

Independent Research in Epidemiology (SPH-E 792) — Summer 2020, Fall 2020

SHORT COURSES

2014—present "Summer Institute on Randomized Behavioral Clinical Trials." Contribute to organizing and teaching a 4-day course with monthly follow-up meetings sponsored by National Cancer Institute. Madison, WI in 2024 and 2025, Salt Lake City, UT in 2026.

Previously a 9-day course sponsored by National Heart, Lung, and Blood Institute. Airlie, VA in 2014—2018. Bethesda, MD in 2019, 2021—2023.

2025 "Systematic Reviews Part 2: Completing a review." Taught a one-day course for the Howard W Odum Institute for Research in Social Science. Chapel Hill, NC.

2025 "Systematic Reviews Part 1: Starting a review." Taught a one-day course for the Howard W Odum Institute for Research in Social Science. Chapel Hill, NC.

2014—2021 "Completing a Cochrane Systematic Review." Taught a two-day course for the US Cochrane Centre. Denver, CO in 2020—2021; Baltimore, MD in 2014—2015.

2015, 2019 "Summer Institute on Strengthening Causal Inference in Behavioral Obesity Research." Contribute to organizing and teaching a one-week course. Bloomington, IN in 2019; Birmingham, AL in 2015.

2015 "Clinical Trials: Assessing Safety and Efficacy for a Diverse Population." Organized and presented at one-day workshop at US Food and Drug Administration. Silver Spring, MD.

2014 "Patient Reported Outcomes Symposium." Organized and presented at a one-day course at Johns Hopkins Bloomberg School of Public Health.

2013 "Beginning a Systematic Review Protocol." Taught a one-day course at UK Cochrane Centre (Oxford, UK)

GUEST LECTURES

UNC Gillings School of Global Public Health

2023—present Design of Clinical Research Studies (EPID 804)

2024 Infectious Disease Seminar (EPID 894)

2024 Intervention Epidemiology (EPID 790)

2024 Environmental Epidemiology (EPID 785)

2023 Epidemiology Doctoral Seminar (EPID 891)

2023 Introduction to Social Epidemiology (EPID 826)

2023 Cancer Epidemiology and Pathogenesis (EPID 770)

2023 Systematic Review (PHLP 702)

Other

2024 International Seminars in Health (online). Universidade Federal de Santa Catarina. Florianópolis, Brazil.

2022 Doctoral Seminar. Department of Epidemiology and Biostatistics, Indiana University School of Public Health.

2019 Doctoral Seminar. Department of Epidemiology and Biostatistics, Indiana University School of Public Health.

2018 Online Programs for Applied Learning Professional Development Seminar: Effective Online Searching (600.611.86). Johns Hopkins Bloomberg School of Public Health.

2014—2018 Graduate Summer Institute of Epidemiology & Biostatistics. Johns Hopkins Bloomberg School of Public Health.

2015 Public Health Nutrition (online course offered continuously). Center for Global Child Health, Sick Kids. Toronto, Canada.

2011—2013 Research Methods. Department of Clinical, Educational, and Health Psychology, University College London.

2007—2011 Psychosocial Interventions. Department of Social Policy and Intervention, University of Oxford.

MENTORING AND ADVISING

Faculty (1)

UNC Gillings School of Global Public Health

2025—present Xiangji Ying. Current position: Assistant Professor, Department of Epidemiology, UNC Gillings School of Global Public Health.

Postdoctoral trainees (2)

UNC Gillings School of Global Public Health

2023—2025 Xiangji Ying. Current position: Assistant Professor, Department of Epidemiology, UNC Gillings School of Global Public Health.

Johns Hopkins Bloomberg School of Public Health

2017—2018 Hwanhee Hong. K99 Mentoring committee member. Current position: Associate Professor, Department of Biostatistics and Bioinformatics, Duke University.

Doctoral dissertation committee, Chair (2)

UNC Gillings School of Global Public Health

2026 Christina Norris Epidemiology
"Examining acute exposure to fine particulate matter, sugarcane burning, and associations with mortality in Costa Rica"

2026 Sherin Ismail Atta Epidemiology
"Comparative effectiveness and harms of belatacept versus tacrolimus among kidney transplant recipients in the United States"

Doctoral dissertation committee (7)

UNC Gillings School of Global Public Health

2025 Jacob Naylor Epidemiology
"The effect of the Holistic Health and Fitness (H2F) system on musculoskeletal injury in United States Army brigades"

2024 Ann Marie Weideman Biostatistics
"Canopy2: Tumor phylogeny inference by bulk DNA and single-cell RNA sequencing & Blinded and partially-unblinded sample size re-estimation for registry-based randomized controlled trials with incomplete event adjudication"

Indiana University School of Public Health

2024 Kevin Naaman Epidemiology (primary advisor 2021—2022)

Johns Hopkins Bloomberg School of Public Health

2017 Nicole Fusco Epidemiology
2016 Kurt Herzer Health Policy and Management
2016 Sheriza Baksh Epidemiology (alternate)

University of Oxford

2014 Sean Grant Social Policy and Intervention

MPH academic advisor and capstone advisor (3)

Johns Hopkins Bloomberg School of Public Health

2018 [1 student]
2017 [2 students]

MSc academic advisor and thesis advisor (29)

University College London, Department of Clinical, Educational & Health Psychology

2014 [1 student]

University of Oxford, Department of Social Policy and Intervention

2011 [11 students]
2010 [6 students]
2009 [6 students]
2008 [5 students]

MPH academic advisor (17)

UNC Gillings School of Global Public Health

2025—2026 [5 students]
2023—2025 [7 students]

Indiana University School of Public Health

2022 [1 student]

Johns Hopkins Bloomberg School of Public Health
2019 [3 students]
2018 [1 student]

Certificate advisor (3)

Indiana University School of Public Health
2020 [1 student] Nutrition Sciences

Johns Hopkins Bloomberg School of Public Health
2018 [2 students] Clinical Trials

Thesis reader or external examiner (2)
2019 [1 student] MHS, Johns Hopkins Bloomberg School of Public Health
2019 [1 student] M Clin Psych, University of Technology Sydney

GRANTS AND CONTRACTS

Amounts are total costs in US dollars.

Ongoing

Improving results and conclusions about harms in systematic reviews of drugs (R01HS029877)
Objective: Use innovative methods to examine whether information about harms in systematic reviews is consistent, and whether reviews address harms identified in real-world evidence and drug labels.
Agency for Healthcare Research and Quality (AHRQ) 2024—2029 (60 months)
Multiple principal investigator (contact) with Halil Kilicoglu $1,918,852 (20% effort)

Peer review management services for PCORI's funded research
Objective: Oversee peer review of all PCORI Final Research Reports, including 11 Associate Editors, contracted through KnowledgeWorks Global with funding from PCORI.
Patient Centered Outcomes Research Institute (PCORI) Continuous renewals since 2022
Principal investigator UNC total for period 2022—2028: $1,560,621 (40% effort)

Innovative approaches to randomized behavioral clinical trials (R25CA287902)
Objective: Provide training to junior faculty in conducting randomized behavioral clinical trials.
National Cancer Institute (NCI) 2024—2028 (48 months)
Consultant (Corrine Voils, PI) $853,773 (none)

Computational methods, resources, and tools to assess transparency and rigor of randomized clinical trials (R01LM014079)
Objective: Use natural language processing to identify methods described in reports of clinical trials, assess adherence to reporting guidelines, and conduct meta-research.
National Library of Medicine (NLM) 2022—2027 (57 months)
Multiple principal investigator with Halil Kilicoglu $1,328,502 (20% effort)

Past

Using GPT to detect outcome switching in randomized clinical trials (cloud resource grant)
Objective: Use innovative approaches, including prompting large language models, to identify outcome switching in clinical trials registered on ClinicalTrials.gov.
AI Acceleration Program, Office of the Provost, University of North Carolina 2025—2026 (12 months)
Principal investigator $30,000 (computing costs only)

Innovative approaches to randomized behavioral clinical trials (R25HL149668)
Objective: Provide training to junior faculty in conducting randomized behavioral clinical trials.
National Heart, Lung, and Blood Institute (NHLBI) 2020—2023 (48 months)
Consultant (Kenneth E. Freedland, PI) $863,078 (none)

Indiana Clinical and Translational Sciences Institute (UL1TR002529)

Objective: To accelerate clinical and translational research by the three research universities, Indiana, Purdue and Notre Dame.

National Center for Advancing Translational Sciences (NCATS) 2019—2022 (parent award 60 months)
Collaborator (joined after award) 5% effort for 2019—2022
(Sharon M Moe, Sarah E Wiehe, George Wodicka, PIs)

Peer review of PCORI's funded research

Objective: Review final reports of PCORI funded research. Evaluate the effectiveness of the peer review process for improving reporting completeness and transparency.

Patient Centered Outcomes Research Institute (PCORI) 2016—2021 (72 months)
Site PI from October 2018 (Mark Helfand, PI) subcontracts total ~$800,000 (20% effort)

Misreported information about harms in trials of gabapentin for neuropathic pain

Objective: Reexamine and publish the harms observed in six clinical trials of gabapentin that were not published or not published completely. Contracted through RIAT Support Center, University of Maryland with funding from Arnold Ventures.

Arnold Ventures (formerly Laura and John Arnold Foundation) 2019—2021 (21 months)
Principal investigator $132,806 (15% effort)

Increasing take-up of TOP by social intervention research journals

Objective: Increase take-up of best practices for openness and transparency by high-impact journals in core disciplines of social intervention research.

Arnold Ventures (formerly Laura and John Arnold Foundation) 2019—2021 (18 months)
Principal investigator $238,975 (20% effort)

Harmonizing data from drug abuse treatment clinical trials at National Institute on Drug Abuse

Objective: Develop a comprehensive user-friendly database of the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) studies.

Arnold Ventures (formerly Laura and John Arnold Foundation) 2018—2021 (36 months)
Co-investigator (Ramin Mojtabai, PI) $500,000 (10% effort)

Mental health services and systems training program (T32MH109436)

Objective: Train pre- and post-doctoral students to lead multi-disciplinary, collaborative research teams.

National Institute of Mental Health (NIMH) 2017—2021
Collaborator (Colleen Barry and Elizabeth Stuart, PIs) $1,064,640 (student support only)

Further increasing take-up of TOP by social intervention research journals

Objective: Expand research designed to increase take-up of best practices for openness and transparency by high-impact journals in core disciplines of social intervention research.

Fetzer Franklin Fund 2020 (12 months)
Co-investigator (Sean Grant, PI) $18,700 (staff costs only)

Scientific review of efforts to improve the evidential value of nutritional epidemiology research

Objective: Host a workshop and prepare a report about rigor and evidence in nutritional epidemiology.

National Cattlemen's Beef Association 2020 (12 months)
Co-investigator (David Allison, PI) $25,200 (meeting and collaborator costs only)

Rigor, reproducibility, and transparency (RRT) at the interdisciplinary interface

Objective: Host a workshop and identify research priorities and opportunities related to RRT.

Sloan Foundation 2019—2020 (12 months)
Co-investigator (David Allison, PI) $19,960 (meeting and collaborator costs only)

TRUST in evaluations of social interventions: Developing standards for federal clearinghouses

Objective: Develop methods for federal clearinghouses to make informed decisions about the quality and transparency of evidence about the effectiveness of social interventions.

Arnold Ventures (formerly Laura and John Arnold Foundation) 2017—2019 (18 months)
Principal investigator $388,053 (20% effort)

Comparative effectiveness research & the Cochrane Eyes & Vision Group (UG1EY020522, year 9)

Objective: Conduct comparative effectiveness research, particularly systematic reviews, related to eyes and vision.

National Eye Institute (NEI) 2018—2019 (12 months)
Co-investigator (Tianjing Li, PI; joined after award) $999,479 in 2018—2019 (10% effort)

Policies and procedures for registering and reporting clinical trials (parent grant UL1TR001079)

Objective: Ancillary award to evaluate the policies, procedures, and resources to ensure clinical trials are registered and reported by academic organizations, and to identify and share best practices.

National Center for Advancing Translational Sciences (NCATS) 2016—2019 (36 months)
Project lead (Daniel E. Ford, PI on the parent grant) ancillary award $50,000 (10% effort)

Estimating population effects in mental health research using meta-analysis (K99MH111807)

Objective: Develop methods to help generalize the results of meta-analyses, apply, and implement findings from meta-analyses of randomized clinical trials in target populations.

National Institute of Mental Health (NIMH) 2017—2018
Mentor (Hwanhee Hong, PI) $117,636 (mentee costs only)

Increasing openness and transparency in research (74420)

Objective: Identify and promote policies and procedures that institutional review boards (IRBs) can use to support open science.

Robert Wood Johnson Foundation (RWJF) 2017—2018 (12 months)
Co-investigator (Sean Grant, PI) $200,000 (5% effort)

Increasing compliance with ClinicalTrials.gov registration and reporting requirements (parent grant U01FD005942)

Objective: Ancillary award to identify policies and procedures related to compliance with federal regulations for clinical trials of FDA regulated products.

US Food and Drug Administration (FDA) 2017—2018 (24 months)
Project lead (Caleb Alexander, PI on the parent grant) ancillary award $80,000 (20% effort)

Comparative effectiveness research & the Cochrane Eyes & Vision Group (U01EY020522, year 7)

Objective: Conduct comparative effectiveness research, particularly systematic reviews, related to eyes and vision.

National Eye Institute (NEI) 2016—2017 (12 months)
Co-investigator (Kay Dickersin, PI; joined after award) $1,333,961 in 2016—2017 (10% effort)

Strengthening social and behavioral science by comparing methods to identify patient important harms (parent grant U01FD004977)

Objective: Ancillary award to compare methods for identifying potential harms and for selecting harms to include in clinical trials.

US Food and Drug Administration (FDA) 2015—2016 (12 months)
Project lead (Caleb Alexander, PI on the parent grant) ancillary award $25,000 (20% effort)

Integrating multiple data sources for meta-analysis to improve patient-centered outcomes (ME-1303-5785)

Objective: Explore the effect of incorporating data from multiple data sources in systematic reviews of patient-centered outcomes research.

Patient Centered Outcomes Research Institute (PCORI) 2013—2015 (24 months)
Co-investigator (Kay Dickersin, PI; joined after award) $761,279 (90% effort)

CONSORT guideline for experiments of psychological, social, and environmental interventions (ES/K00087X/1)

Objective: Develop reporting guidelines for randomized controlled trials of psychological and behavioral interventions.

Economic and Social Research Council (UK) 2013—2015 (24 months)
Principal investigator with Paul Montgomery ~$519,906 [279,681 GBP] (10% effort)

Focus group study to increase uptake and acceptability of self-help

Objective: Identify factors that might relate to the uptake and use of self-help materials for people with anxiety disorders.

University Counseling Service, University of Oxford 2008 (12 months)
Principal investigator ~$6,000 [3000 GBP] (study expenses only)

Training grant

Objective: To complete a training course in qualitative research methods.

Department of Social Policy and Intervention, University of Oxford 2007 (6 months)
Principal investigator ~$1,560 [780 GBP] (training cost only)

ACADEMIC SERVICE

School or university level

Graduate School, UNC-Chapel Hill

2026—present *Member*, Dissertation Completion Fellowship Committee

North Carolina Translational and Clinical Sciences (NC TraCS) Institute, UNC-Chapel Hill

2026 *Member*, CTS Pilot Study Section

Indiana University School of Public Health-Bloomington

2019—2022 *Member*, Community, Healthcare Delivery, & Implementation Science Project Development Team (PDT), Indiana Clinical and Translational Sciences Institute

2020—2021 *Chair*, Academic Council (governing body of IU SPH-B)

2021 *Member*, Taskforce on Diversity and Inclusion

2019—2020 *Member*, Academic Council (governing body of IU SPH-B)

2019 *Member*, Faculty Grievance Committee

Department level

Department of Epidemiology, UNC Gillings School of Global Public Health

2023—present *Member*, Doctoral Admissions Committee

2023—2025 *Member*, MPH Advisors *ad hoc* committee

2023—2024 *Member*, Department Chair Search Committee

Department of Epidemiology and Biostatistics, Indiana University-Bloomington

2019—2021 *Member*, Doctoral Admissions Committee

2021 *Member*, Curriculum Committee

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health

2014—2019 *Member*, MPH and Doctoral Admissions Committee, Clinical Trials and Evidence Synthesis Track

Department of Social Policy and Intervention, University of Oxford

2008—2011 *Member*, Student Support Committee

2008—2011 *Member*, MSc and DPhil Admissions Committee
2008—2011 *Member*, Exam Board
2007—2011 *Member*, Teaching Committee (equivalent to Graduate Studies Committee)

PROFESSIONAL SERVICE

Professional committees

2024—present *Member*, Cochrane Methods Executive
2023—present *Associate Convenor*, Cochrane Adverse Events Methods Group
2023—present *Member*, American Psychological Association Open Science and Methodology Expert Panel
2023—present *Member*, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Executive Committee
2023—present *Member*, Summer Institute on Randomized Behavioral Clinical Trials Steering Committee
2022—present *Member*, MRC-NIHR Trials Methodology Research Partnership (TMRP) Adverse Events in Clinical Trials Working Group
2022—present *Member*, JBI Evidence Synthesis Taxonomy Initiative Advisory Group (2022—2026) and Executive Committee (2026—present)
2016—2025 *Member*, Transparency and Openness Promotion (TOP) Guidelines Advisory Committee
2023—2024 *Member*, National Academies of Sciences, Engineering, and Medicine Committee to Review Relevant Literature Regarding Adverse Events Associated with Vaccines
2019—2022 *Member*, American Psychological Association Advisory Steering Committee for Development of Clinical Practice Guidelines
2021 *Member*, National Academies of Sciences, Engineering, and Medicine Committee to Review a Department of Veterans Affairs Monograph on Health Economic Effects of Service Dogs for Veterans with Post Traumatic Stress Disorder
2020—2021 *Member*, National Academies of Sciences, Engineering, and Medicine Committee to Review a Department of Veterans Affairs Monograph (No. 1) on Potential Effects of Service and Emotional Support Dogs on Post-Traumatic Stress Disorder (therapeutic effects)
2019—2021 *Member*, American Psychological Association Emotion Regulation Clinical Practice Guideline Working Group
2019 *Member*, Cochrane Clinical Study Report Working Group
2019 *Member*, Instrument for reporting Planned Endpoints in Clinical Trials (INSPECT) Consensus Group
2019 *Member*, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Update Consensus Group
2019 *Member*, Consolidated Standards of Reporting Trials (CONSORT) Extension for Harms Consensus Group
2016—2019 *Member*, Multi Stakeholder Engagement (MuSE) Consortium
2018 *Member*, Guidance for Exploratory Studies of Complex Public Health Interventions (GUEST) Consensus Meeting
2015—2018 *Member*, American Psychological Association Journal Article Reporting Standards (JARS) Taskforce
2017 *Member*, NIH Office of Behavioral and Social Sciences Research (OBSSR) Working Group for Comparator Selection in Behavioral and Social Science Trials
2017 *Member*, NIH Science of Behavior Change (SOBC) Good Clinical Practice Workshop
2014 *Member*, Consolidated Standards of Reporting Trials Extension for Social and Psychological Interventions (CONSORT-SPI) Consensus Group Executive Committee

2012—2014 *Member*, National Institute for Health and Care Excellence (UK) Guideline Development Group, Bipolar Disorder

2011—2013 *Member*, National Institute for Health and Care Excellence (UK) Guideline Development Group, Psychosis and Schizophrenia in Adults

2011—2013 *Member*, National Institute for Health and Care Excellence (UK) Guideline Development Group, Social Anxiety Disorder

External review letters

2023 External promotion review, University of Colorado Boulder

2023 External promotion review, Johns Hopkins Bloomberg School of Public Health

2022 External promotion review, University of Arkansas for Medical Sciences

2021 External promotion review, Yale School of Medicine

Editorial boards

2026—present *Editorial Board Member*, Cochrane Evidence Synthesis and Methods

2022—present *Co-Scientific Director*, Peer Review of Patient Centered Outcomes Research Institute (PCORI) Final Research Reports

2019—present *Editorial Board Member*, Journal of Clinical Epidemiology

2019—2026 *Associate Editor*, Trials

2019—2025 *Associate Editor*, American Journal of Public Health

2016—2022 *Consulting Editor*, Health Psychology

2016—2022 *Associate Editor*, Peer Review of Patient Centered Outcomes Research Institute (PCORI) Final Research Reports

2019—2022 *Guest Editor* for special issue on meta-analysis, Prevention Science

2011—2018 *Editorial Board Member*, Research on Social Work Practice

2013—2016 *Associate Editor*, Systematic Reviews

2005—2006 *Managing Editor*, Campbell Collaboration Crime and Justice Group

Conference organizing committees

2020 *Scientific Committee Member*, International Behavioral Trials Network

2017 *Abstract Committee Member*, Global Evidence Summit

2016 *Abstract Committee Member*, Cochrane Colloquium

2010 *Abstract Committee Member*, Cochrane and Campbell Colloquium

Ad hoc peer reviewer

160 peer reviews since ~2010 verified on Web of Science, excluding manuscripts handled as journal editor.

Addiction, *Advances in Methods and Practices in Psychological Science (AMPPS)*, *American Journal of Epidemiology*, *American Journal of Public Health (AJPH)*, *American Psychologist*, *Annals of Behavioral Medicine*, *Annals of Internal Medicine*, *BMC Medical Research Methodology*, *BMC Medicine*, *BMJ*, *BMJ Open*, *British Journal of Clinical Psychology*, *British Journal of Psychiatry*, *Cochrane*, *Cochrane Evidence Synthesis and Methods*, *Cognitive Behaviour Therapy*, *Depression and Anxiety*, *Health Psychology*, *JAMA*, *JAMA Internal Medicine*, *JAMA Network Open*, *JAMA Psychiatry*, *Journal of Clinical Epidemiology*, *Journal of the American Medical Informatics Association (JAMIA)*, *Nature Medicine*, *Pharmacoepidemiology and Drug Safety*, *PLOS ONE*, *Prevention Science*, *Psychological Medicine*, *Research Integrity and Peer Review*, *Review of Educational Research*, *Systematic Reviews*, *Trials*